Novo Integrated Sciences (NVOS) 10-Q 24 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Nov. 30, 2022	May 24, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Nov. 30, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--08-31
Entity File Number	001-40089
Entity Registrant Name	Novo Integrated Sciences, Inc.
Entity Central Index Key	0001138978
Entity Tax Identification Number	59-3691650
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	11120 NE 2nd Street
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Bellevue
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98004
City Area Code	(206)
Local Phone Number	617-9797
Title of 12(b) Security	Common Stock
Trading Symbol	NVOS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		144,857,518

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Nov. 30, 2022	Aug. 31, 2022
Current Assets:
Cash and cash equivalents	$ 878,700	$ 2,178,687
Accounts receivable, net	960,091	1,017,405
Inventory, net	1,010,115	879,033
Other receivables, current portion	1,053,437	1,085,335
Prepaid expenses and other current assets	554,978	571,335
Total current assets	4,457,321	5,731,795
Property and equipment, net	5,563,829	5,800,648
Intangible assets, net	17,708,310	18,840,619
Right-of-use assets, net	2,423,519	2,673,934
Goodwill	7,595,844	7,825,844
TOTAL ASSETS	37,748,823	40,872,840
Current Liabilities:
Accounts payable	2,075,124	1,800,268
Accrued expenses	1,232,519	1,116,125
Accrued interest (including amounts to related parties)	434,521	454,189
Convertible notes payable, net of discount of $2,750,917	6,422,009	9,099,654
Derivative liability	1,390,380
Contingent liability	62,855	534,595
Due to related parties	417,718	478,897
Finance lease liability, current portion	8,737	8,890
Operating lease liability, current portion	521,358	582,088
Total current liabilities	12,565,221	14,074,706
Debentures, related parties	918,439	946,250
Government loans and notes payable, net of current portion	157,900	161,460
Finance lease liability, net of current portion	9,466	12,076
Operating lease liability, net of current portion	2,010,041	2,185,329
Deferred tax liability	1,402,966	1,445,448
TOTAL LIABILITIES	17,064,033	18,825,269
Commitments and contingencies
Novo Integrated Sciences, Inc.
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at November 30, 2022 and August 31, 2022, respectively
Common stock; $0.001 par value; 499,000,000 shares authorized; 39,890,811 and 31,180,603 shares issued and outstanding at November 30, 2022 and August 31, 2022, respectively	39,891	31,181
Additional paid-in capital	69,135,417	66,056,824
Common stock to be issued (4,113,411 and 4,149,633 shares at November 30, 2022 and August 31, 2022)	9,382,441	9,474,807
Other comprehensive income	143,828	560,836
Accumulated deficit	(57,753,902)	(53,818,489)
Total Novo Integrated Sciences, Inc. stockholders’ equity	20,947,675	22,305,159
Noncontrolling interest	(262,885)	(257,588)
Total stockholders’ equity	20,684,790	22,047,571
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 37,748,823	$ 40,872,840

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Nov. 30, 2022	Aug. 31, 2022
Statement of Financial Position [Abstract]
Convertible notes payable net of discount current	$ 2,750,917
Convertible preferred stock, par value	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	1,000,000	1,000,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	499,000,000	499,000,000
Common stock, shares issued	39,890,811	31,180,603
Common stock, shares outstanding	39,890,811	31,180,603
Common stock to be issued, shares	4,113,411	4,149,633

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Income Statement [Abstract]
Revenues	$ 3,419,280	$ 3,161,927
Cost of revenues	1,679,747	1,895,461
Gross profit	1,739,533	1,266,466
Operating expenses:
Selling expenses	7,332	168
General and administrative expenses	3,974,161	2,629,957
Total operating expenses	3,981,493	2,630,125
Loss from operations	(2,241,960)	(1,363,659)
Non-operating income (expense)
Interest income	2,281	8,388
Interest expense	(167,243)	(68,730)
Amortization of debt discount	(1,490,513)	(57,840)
Foreign currency transaction losses	(39,301)	(334,554)
Total other income (expense)	(1,694,776)	(452,736)
Loss before income taxes	(3,936,736)	(1,816,395)
Income tax expense
Net loss	(3,936,736)	(1,816,395)
Net loss attributed to noncontrolling interest	(1,323)	(9,808)
Net loss attributed to Novo Integrated Sciences, Inc.	(3,935,413)	(1,806,587)
Comprehensive loss:
Foreign currency translation loss	(420,982)	(104,388)
Comprehensive loss:	$ (4,357,718)	$ (1,920,783)
Weighted average common shares outstanding - basic and diluted	33,855,082	26,924,705
Net loss per common share - basic and diluted	$ (0.12)	$ (0.07)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Common Stock to be Issued [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total Novo Stockholders Equity [Member]	Noncontrolling Interest [Member]	Total
Balance at Aug. 31, 2021	$ 26,610	$ 54,579,396	$ 9,236,607	$ 991,077	$ (20,969,274)	$ 43,864,416	$ (60,261)	$ 43,804,155
Balance, shares at Aug. 31, 2021	26,610,144
Fair value of stock options		154,135				154,135		154,135
Foreign currency translation loss				(103,533)		(103,533)	(855)	(104,388)
Net loss					(1,806,587)	(1,806,587)	(9,808)	(1,816,395)
Common stock for services	$ 35	64,715				64,750		64,750
Common stock for services, shares	35,000
Common stock issued as collateral and held in escrow	$ 2,000	(2,000)
Common stock issued as collateral and held in escrow, shares	2,000,000
Common stock to be issued for purchase of Terragenx			983,925			983,925	97,311	1,081,236
Common stock to be issued for purchase of Mullin assets			188,925			188,925		188,925
Value of warrants issued with convertible notes		295,824				295,824		295,824
Balance at Nov. 30, 2021	$ 28,645	55,092,070	10,409,457	887,544	(22,775,861)	43,641,855	26,387	43,668,242
Balance, shares at Nov. 30, 2021	28,645,144
Balance at Aug. 31, 2022	$ 31,181	66,056,824	9,474,807	560,836	(53,818,489)	22,305,159	(257,588)	22,047,571
Balance, shares at Aug. 31, 2022	31,180,603
Units issued for cash, net of offering costs	$ 4,000	1,791,000				1,795,000		1,795,000
Units issued for cash, net of offering costs, shares	4,000,000
Issuance of common stock to be issued	$ 36	92,330	(92,366)
Issuance of common stock to be issued, shares	36,222
Cashless exercise of warrants	4,674	1,134,376				1,139,050		1,139,050
Cashless exercise of warrants, shares	4,673,986
Fair value of stock options		60,887				60,887		60,887
Foreign currency translation loss				(417,008)		(417,008)	(3,974)	(420,982)
Net loss					(3,935,413)	(3,935,413)	(1,323)	$ (3,936,736)
Common stock issued as collateral and held in escrow, shares	4,000,000							4,000,000
Balance at Nov. 30, 2022	$ 39,891	$ 69,135,417	$ 9,382,441	$ 143,828	$ (57,753,902)	$ 20,947,675	$ (262,885)	$ 20,684,790
Balance, shares at Nov. 30, 2022	39,890,811

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,936,736)	$ (1,816,395)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	586,166	694,282
Fair value of vested stock options	60,887	154,135
Financing costs for debt extension	1,139,050
Common stock issued for services		64,750
Operating lease expense	209,846	163,879
Amortization of debt discount	1,490,513	57,840
Foreign currency transaction losses	39,301	334,554
Changes in operating assets and liabilities:
Accounts receivable	28,174	(253,079)
Inventory	(157,118)	12,245
Prepaid expenses and other current assets	1,471	(47,335)
Accounts payable	321,961	(55,056)
Accrued expenses	149,945	82,933
Accrued interest	(9,232)	9,481
Operating lease liability	(202,465)	(161,337)
Net cash used in operating activities	(278,237)	(759,103)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(120,397)
Cash acquired with acquisition		29,291
Net cash used in investing activities		(91,106)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments to related parties	(48,480)	(3,127)
Repayments of finance leases	(2,763)	(7,088)
Repayment of convertible notes	(2,777,778)
Proceeds from the sale of units, net of offering costs	1,795,000
Proceeds from issuance of convertible notes, net		1,410,000
Net cash (used in) provided by financing activities	(1,034,021)	1,399,785
Effect of exchange rate changes on cash and cash equivalents	12,271	(41,984)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(1,299,987)	507,592
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	2,178,687	8,293,162
CASH AND CASH EQUIVALENTS, END OF PERIOD	878,700	8,800,754
CASH PAID FOR:
Interest	186,911	64,522
Income taxes
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Debt discount recognized on derivative liability	1,390,380
Common stock to be issued for intangible assets		188,925
Common stock to be issued for acquisition		$ 983,925

Organization and Basis of Prese

Organization and Basis of Presentation	3 Months Ended
	Nov. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Note 1 - Organization and Basis of Presentation Organization and Line of Business Novo Integrated Sciences, Inc. (“Novo Integrated”) was incorporated in Delaware on November 27, 2000, under the name Turbine Truck Engines, Inc. On February 20, 2008, the Company was re-domiciled to the State of Nevada. Effective July 12, 2017, the Company’s name was changed to Novo Integrated Sciences, Inc. When used herein, the terms the “Company,” “we,” “us” and “our” refer to Novo Integrated and its consolidated subsidiaries. The Company owns Canadian and U.S. subsidiaries which provide, or intend to provide, essential and differentiated solutions to the delivery of multidisciplinary primary care and related wellness products through the integration of medical technology, interconnectivity, advanced therapeutics, diagnostic solutions, unique personalized product offerings, and rehabilitative science. We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered now and how it will be delivered in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective and efficient healthcare distribution. The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers: ● First Pillar – Service Networks: Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities. ● Second Pillar – Technology: Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home. ● Third Pillar – Products: Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions. On April 25, 2017 (the “Effective Date”), we entered into a Share Exchange Agreement (the “Share Exchange Agreement”) by and between (i) Novo Integrated; (ii) Novo Healthnet Limited (“NHL”), (iii) ALMC-ASAP Holdings Inc. (“ALMC”); (iv) Michael Gaynor Family Trust (the “MGFT”); (v) 1218814 Ontario Inc. (“1218814”); and (vi) Michael Gaynor Physiotherapy Professional Corp. (“MGPP,” and together with ALMC, MGFT and 1218814, the “NHL Shareholders”). Pursuant to the terms of the Share Exchange Agreement, Novo Integrated agreed to acquire, from the NHL Shareholders, all of the shares of both common and preferred stock of NHL held by the NHL Shareholders in exchange for the issuance, by Novo Integrated to the NHL Shareholders, of shares of Novo Integrated common stock such that following the closing of the Share Exchange Agreement, the NHL Shareholders would own 16,779,741 85 On May 9, 2017, the Exchange closed and, as a result, NHL became a wholly owned subsidiary of Novo Integrated. The Exchange was accounted for as a reverse acquisition under the purchase method of accounting since NHL obtained control of Novo Integrated Sciences, Inc. Accordingly, the Exchange was recorded as a recapitalization of NHL, with NHL being treated as the continuing entity. The historical financial statements presented are the financial statements of NHL. The Share Exchange Agreement was treated as a recapitalization and not as a business combination; therefore, no pro forma information is disclosed. At the closing date of the Exchange, the net assets of the legal acquirer, Novo Integrated Sciences, Inc., were $ 6,904 Reverse Stock Split On February 1, 2021, the Company effected a 1-for-10 reverse stock split of our common stock. As a result of the reverse stock split, every 10 shares of issued and outstanding common stock were exchanged for one share of common stock, with any fractional shares being rounded up to the next higher whole share. Unless otherwise noted, the share and per share information in this report have been retroactively adjusted to give effect to the 1-for-10 reverse stock split Impact of COVID-19 While all of the Company’s business units are operational at the time of this filing, any future impact of the COVID-19 pandemic on the Company’s operations remains unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced patient traffic and reduced operations. For more information regarding the impact of COVID-19 on the Company, see “Part I, Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Financial Impact of COVID-19” of this quarterly report on Form 10-Q. Basis of Presentation The accompanying unaudited condensed consolidated financial statements were prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The information furnished herein reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management, are necessary to fairly state the Company’s financial position, the results of its operations, and cash flows for the periods presented. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with U.S. GAAP were omitted pursuant to such rules and regulations. The financial information contained in this report should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended August 31, 2022, that the Company filed on April 3, 2023. The results of operations for the three months ended November 30, 2022 are not necessarily indicative of the results for the fiscal year ending August 31, 2023. The Company’s Canadian subsidiaries’ functional currency is the Canadian Dollar (“CAD”) and the parent company’s functional currency is the United States Dollar (“$” or “USD”); however, the accompanying unaudited condensed consolidated financial statements were translated and presented in USD. Going Concern The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements are issued. The Company has incurred recurring losses from operations, has negative cash flows from operating activities, and has an accumulated deficit as at November 30, 2022. The Company believes that its cash and other available resources may not be sufficient to meet its operating needs and the payment of obligations related to various business acquisitions as they come due within one year after the date the unaudited condensed consolidated financial statements are issued. To alleviate these conditions, the Company is currently in the process of raising funds through a debt financing and a subsequent public offering in the United States. As the Company’s funding activities are ongoing, there can be no assurances that the Company will be able to secure funding on terms that are acceptable to the Company, or at all. These conditions, along with the matters noted above, raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements are issued. While management has developed and is in process to implement plans that management believes could alleviate in the future the substantial doubt that was raised, management concluded at the date of the issuance of the unaudited condensed consolidated financial statements that substantial doubt exists as those plans are not completely within the control of management. These unaudited condensed consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and consolidated balance sheets classifications that would be necessary if the Company were unable to realize its assets and settle its liabilities as a going concern in the normal course of operations. Such adjustments could be material. Foreign Currency Translation The accounts of the Company’s Canadian subsidiaries are maintained in CAD. The accounts of these subsidiaries are translated into USD in accordance with the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 830, Foreign Currency Transaction Comprehensive Income Schedule of Foreign Currency Translation, Exchange Rate Used November 30, 2022 November 30, 2021 August 31, 2022 Period end: CAD to USD exchange rate $ 0.7403 $ 0.7807 $ 0.7627 Average period: CAD to USD exchange rate $ 0.7414 $ 0.7961 $ 0.7864

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Nov. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to going concern assessment, useful lives of non-current assets, impairment of non-current assets, allowance for doubtful receivables, allowance for slow moving and obsolete inventory, valuation of share-based compensation and warrants, and valuation allowance for deferred tax assets. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and entities it controls including its wholly owned subsidiaries, NHL, Acenzia Inc. (“Acenzia”), Novomerica Health Group, Inc. (“NHG”), Novo Healthnet Rehab Limited, Novo Assessments Inc., PRO-DIP, LLC (“PRO-DIP”), a 91 50.1 80 70 All intercompany transactions have been eliminated. An entity is controlled when the Company has the ability to direct the relevant activities of the entity, has exposure or rights to variable returns from its involvement with the entity, and is able to use its power over the entity to affect its returns from the entity. Income or loss and each component of other comprehensive income (“OCI”) are attributed to the shareholders of the Company and to the noncontrolling interests. Total comprehensive loss is attributed to the shareholders of the Company and to the noncontrolling interests even if this results in the non-controlling interests having a deficit balance on consolidation. Noncontrolling Interest The Company follows FASB ASC Topic 810, Consolidation, The net income (loss) attributed to the NCI is separately designated in the accompanying condensed consolidated statements of operations and comprehensive loss. Cash Equivalents For the purpose of the condensed consolidated statements of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less. Accounts Receivable Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of November 30, 2022 and August 31, 2022, the allowance for uncollectible accounts receivable was $ 957,375 992,329 Inventory Inventories are valued at the lower of cost (determined by the first in, first out method) and net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. Inventory is segregated into three areas: raw materials, work-in-process and finished goods. The Company periodically assessed its inventory for slow moving and/or obsolete items and any change in the allowance is recorded in cost of revenues in the accompanying condensed consolidated statements of operations and comprehensive loss. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired. As of November 30, 2022 and August 31, 2022, the Company’s allowance for slow moving or obsolete inventory was $ 997,467 1,027,670 Other Receivables Other receivables are recorded at cost and presented as current or long-term based on the terms of the agreements. Management reviews the collectability of other receivables and writes off the portion that is deemed to be uncollectible. During the period/year ended November 30, 2022 and August 31, 2022, the Company wrote off $ nil 299,672 225,924 73,748 Property and Equipment Property and equipment are stated at cost less depreciation and impairment. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows: Schedule of Estimated Useful Lives of Assets Building 30 Leasehold improvements 5 Clinical equipment 5 Computer equipment 3 Office equipment 5 Furniture and fixtures 5 Leases The Company applies the provisions of ASC Topic 842, Leases Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment no Intangible Assets The Company’s intangible assets are being amortized over their estimated useful lives as follows: Schedule of Intangible Assets Amortized Estimated Useful Lives Land use rights 50 Intellectual property 7 Customer relationships 5 Brand names 7 The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Based on its reviews at November 30, 2022, the Company believes there was no impairment of its intangible assets. Right-of-use Assets The Company’s right-of-use assets consist of leased assets recognized in accordance with ASC 842, Leases, which 12 months Goodwil Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under U.S. GAAP, goodwill is not amortized but is subject to annual impairment tests. The Company recorded goodwill related to its acquisition of APKA Health, Inc. (“APKA”) during the fiscal year ended August 31, 2017, Executive Fitness Leaders (“EFL”) during the fiscal year ended August 31, 2018, Action Plus Physiotherapy Rockland (“Rockland”) during the fiscal year ended August 31, 2019, Acenzia during the fiscal year ended August 31, 2021, and 1285 Canada during the fiscal year ended August 31, 2022. As of August 31, 2022, the Company performed the required impairment reviews and determined that an impairment charge of $ 1,357,043 Summary of changes in goodwill by acquired businesses is as follows: Schedule of Changes in Goodwill APKA EFL Rockland Acenzia 1285 Canada Total Balance, August 31, 2021 $ 197,925 $ 129,839 $ 229,593 $ 8,931,491 $ - $ 9,488,848 Goodwill acquired with purchase of business - - - - 602 602 Impairment of goodwill - - - (1,357,043 ) - (1,357,043 ) Foreign currency translation adjustment (7,247 ) (4,751 ) (8,405 ) (286,141 ) (19 ) (306,563 ) Balance, August 31, 2022 $ 190,678 $ 125,088 $ 221,188 $ 7,288,307 $ 583 $ 7,825,844 Beginning balance $ 190,678 $ 125,088 $ 221,188 $ 7,288,307 $ 583 $ 7,825,844 Foreign currency translation adjustment (5,600 ) (3,673 ) (6,507 ) (214,203 ) (17 ) (230,000 ) Balance, November 30, 2022 $ 185,078 $ 121,415 $ 214,681 $ 7,074,104 $ 566 $ 7,595,844 Ending balance $ 185,078 $ 121,415 $ 214,681 $ 7,074,104 $ 566 $ 7,595,844 Fair Value of Financial Instruments For certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, other receivables, accounts payable, accrued expenses, current portion of finance and operating lease liability, and due to related parties, the carrying amounts approximate their fair values due to their short-term maturities. FASB ASC Topic 820, Fair Value Measurements and Disclosures Financial Instruments ● Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement. The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity Derivatives and Hedging For certain financial instruments, the carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, other receivables, and current liabilities, including accounts payable, short-term notes payable, due to related parties, operating lease liability and finance lease liability, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The carrying value of notes payable approximates their fair values due to current market rate on such debt. As of November 30, 2022 and August 31, 2022, respectively, the Company did not identify any financial assets and liabilities required to be presented on the condensed consolidated balance sheet at fair value, except for cash and cash equivalents which are carried at fair value using Level 1 inputs and derivative liability which is carried at fair value using level 3 inputs. Derivative Financial Instruments Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments and measurement of their fair value for accounting purposes. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt under ASC 470, the Company will continue its evaluation process of these instruments as derivative financial instruments under ASC 815. The Company applies the guidance in ASC 815-40-35-12 to determine the order in which each convertible instrument would be evaluated for derivative classification. Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to the fair value of derivatives. Revenue Recognition The Company’s revenue recognition reflects the updated accounting policies as per the requirements of FASB Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers Revenue from providing healthcare and healthcare related services and product sales are recognized under Topic 606 ● executed contracts with the Company’s customers that it believes are legally enforceable; ● identification of performance obligations in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. These five elements, as applied to the Company’s revenue category, are summarized below: ● Healthcare and healthcare related services – gross service revenue is recorded in the accounting records at the time the services are provided (point-in-time) on an accrual basis at the provider’s established rates. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes. ● Product sales – revenue is recorded at the point of time of delivery In arrangements where another party is involved in providing specified services to a customer, the Company evaluates whether it is the principal or agent. In this evaluation, the Company considers if the Company obtains control of the specified goods or services before they are transferred to the customer, as well as other indicators such as the party primarily responsible for fulfillment, inventory risk, and discretion in establishing price. For product sales where the Company is not the principal, the Company recognizes revenue on a net basis. For the periods presented, revenue for arrangements where the Company is the agent was not material. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue. Unearned revenue is included with accrued expenses in the accompanying condensed consolidated balance sheets. Sales returns and allowances were insignificant for the periods ended November 30, 2022 and 2021. The Company does not provide unconditional right of return, price protection or any other concessions to its customers. Income Taxes The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented. Stock-Based Compensation The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation Basic and Diluted Earnings Per Share Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share 18,609,499 4,509,530 4,441,359 4,113,411 Due to the net loss incurred potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss per share for all periods presented. Foreign Currency Transactions and Comprehensive Income U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the CAD and the functional currency of the parent company is the United States dollar. Translation losses of $ 420,982 431,605 Statement of Cash Flows Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the condensed consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the condensed consolidated balance sheets. Segment Reporting ASC Topic 280, Segment Reporting Reclassifications Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or shareholders’ equity. Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying condensed consolidated financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Nov. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 3 – Related Party Transactions Due to related parties Amounts loaned to the Company by stockholders and officers of the Company are payable upon demand and unsecured. At November 30, 2022 and August 31, 2022, the amount due to related parties was $ 417,718 478,897 335,710 21,304 6 60,704 13.75 394,405 21,949 6 62,543 13.75

Accounts Receivables, net

Accounts Receivables, net	3 Months Ended
	Nov. 30, 2022
Receivables [Abstract]
Accounts Receivables, net	Note 4 – Accounts Receivables, net Accounts receivables, net at November 30, 2022 and August 31, 2022 consisted of the following: Schedule of Accounts Receivables, Net November 30, August 31, 2022 2022 Trade receivables $ 1,828,732 $ 1,829,475 Amounts earned but not billed 88,734 180,259 Accounts receivable gross 1,917,466 2,009,734 Allowance for doubtful accounts (957,375 ) (992,329 ) Accounts receivable, net $ 960,091 $ 1,017,405

Inventory

Inventory	3 Months Ended
	Nov. 30, 2022
Inventory Disclosure [Abstract]
Inventory	Note 5 – Inventory Inventory at November 30, 2022 and August 31, 2022 consisted of the following: Schedule of Inventory November 30, August 31, 2022 2022 Raw materials $ 1,380,358 $ 1,259,954 Work in process 135,238 139,333 Finished Goods 491,986 507,416 Inventory Gross 2,007,582 1,906,703 Allowance for slow moving and obsolete inventory (997,467 ) (1,027,670 ) Inventory, net $ 1,010,115 $ 879,033

Other Receivables

Other Receivables	3 Months Ended
	Nov. 30, 2022
Receivables [Abstract]
Other Receivables	Note 6 – Other Receivables Other receivables at November 30, 2022 and August 31, 2022 consisted of the following: Schedule of Other Receivables November 30, August 31, 2022 2022 - 74,030 76,272 Advance to corporation; accrues interest at 12 January 31, 2024 74,030 76,272 Advance to corporation; accrues interest at 12 September 1, 2023 535,327 551,536 Advance to corporation; accrues interest at 10 September 1, 2023 444,080 457,527 Total other receivables 1,053,437 1,085,335 Current portion (1,053,437 ) (1,085,335 ) Long-term portion $ - $ -

Property and Equipment

Property and Equipment	3 Months Ended
	Nov. 30, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 7 – Property and Equipment Property and equipment at November 30, 2022 and August 31, 2022 consisted of the following: Schedule of Property and Equipment November 30, August 31, 2022 2022 Land $ 444,181 $ 457,631 Building 3,331,359 3,432,232 Leasehold improvements 842,853 868,375 Clinical equipment 1,870,986 1,927,639 Computer equipment 33,563 34,579 Office equipment 44,552 45,406 Furniture and fixtures 38,356 39,518 Property and equipment gross 6,605,850 6,805,380 Accumulated depreciation (1,042,021 ) (1,004,732 ) Total $ 5,563,829 $ 5,800,648 Depreciation expense for the three months ended November 30, 2022 and 2021 was $ 60,043 74,606 Certain property and equipment have been used to secure notes payable (See Note 10).

Intangible Assets

Intangible Assets	3 Months Ended
	Nov. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 8 – Intangible Assets Intangible assets at November 30, 2022 and August 31, 2022 consisted of the following: Schedule of Intangible Assets November 30, August 31, 2022 2022 Land use rights $ 11,573,321 $ 11,573,321 Intellectual property 7,503,709 8,059,386 Customer relationships 2,292,655 2,320,154 Brand names 1,931,818 1,990,314 Finite lived intangible assets, gross 23,301,503 23,943,175 Accumulated amortization (5,593,193 ) (5,102,556 ) Total $ 17,708,310 $ 18,840,619 Amortization expense for the three months ended November 30, 2022 and 2021 was $ 526,123 619,676 Expected amortization expense of intangible assets over the next 5 years and thereafter is as follows: Schedule of Expected Amortization Expense of Intangible Assets Twelve Months Ending November 30, 2023 $ 2,002,793 2024 2,002,793 2025 1,819,531 2026 1,457,184 2027 1,206,276 Thereafter 9,219,733 Total $ 17,708,310

Accrued Expenses

Accrued Expenses	3 Months Ended
	Nov. 30, 2022
Payables and Accruals [Abstract]
Accrued Expenses	Note 9 – Accrued Expenses Accrued expenses at November 30, 2022 and August 31, 2022 consisted of the following: Schedule of Accrued Expenses November 30, August 31, 2022 2022 Accrued liabilities $ 972,344 $ 884,024 Accrued payroll 224,394 195,214 Unearned revenue 35,781 36,887 Accrued expenses $ 1,232,519 $ 1,116,125

Government Loans and Notes Paya

Government Loans and Notes Payable	3 Months Ended
	Nov. 30, 2022
Government Loans And Notes Payable
Government Loans and Notes Payable	Note 10 – Government Loans and Notes Payable Notes payable at November 30, 2022 and August 31, 2022 consisted of the following: Schedule of Governmental Loans and Note Payable November 30, August 31, 2022 2022 Government loans issued under the Government of Canada’s Canada Emergency Business Account (“CEBA”) program (A). 88,836 91,526 Note payable to the Small Business Administration (“SBA”). The note bears interest at 3.75 monthly 190 30 40,320 40,320 Note payable dated December 3, 2018; accrues interest at 4.53 annual 4,000 December 31, 2028 28,744 29,614 Total government loans and notes payable 157,900 161,460 Less current portion - - Long-term portion $ 157,900 $ 161,460 (A) The Government of Canada launched CEBA loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained CAD$ 80,000 59,224 December 31, 2023 If the loan amount is paid on or before December 31, 2023, 25 75 60,000 20,000 29,612 Future scheduled maturities of outstanding government loans and notes payable are as follows: Schedule of Future Maturities Outstanding of Governmental Loans and Note Payable Twelve Months Ending November 30, 2023 $ 6,242 2024 95,079 2025 6,242 2026 6,242 2027 6,242 Thereafter 37,853 Total $ 157,900

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended
	Nov. 30, 2022
Convertible Notes Payable
Convertible Notes Payable	Note 11 – Convertible Notes Payable Novo Integrated On December 14, 2021, Novo Integrated issued two convertible notes payable for a total of $ 16,666,666 8,333,333 5 June 14, 2023 2.00 In connection with the $16.66m+ convertible notes, the Company issued the note holders warrants to purchase a total of 5,833,334 2.00 December 14, 2025 7,680,156 ● Expected life of 4.0 ● Volatility of 275 ● Dividend yield of 0 ● Risk free interest rate of 1.23 The face amount of the $16.66m+ convertible notes of $ 16,666,666 was proportionately allocated to the $16.66m+ convertible notes and the warrants in the amount of $ 11,409,200 and $ 5,257,466 , respectively. The amount allocated to the warrants of $ 5,257,466 was recorded as a discount to the convertible note and as additional paid in capital. The $16.66m+ convertible notes contained an original issue discount totaling $ 1,666,666 and the Company also incurred $ 1,140,000 in loan fees in connection with the $16.66m+ convertible notes. The combined total discount is $ 8,064,132 and will be amortized over the life of the $16.66m+ convertible notes. On November 14, 2022, the $16.66m+ convertible notes were amended to provide the holders with conversion rights consisting of a conversion price to the first $ 1,000,000 (i) the conversion price in effect at such time and (ii) 82.0% of the lowest VWAP during the five (5) trading days immediately prior to a conversion date. The Company determined that the conversion features of these notes represented embedded derivatives since the notes are convertible into a variable number of shares upon conversion. 1,390,380 nil ● Expected life of 0.58 ● Volatility of 148.20% ● Dividend yield of 0% ● Risk free interest rate of 4.55% The derivative was recorded as a discount on the convertible notes, but only for an amount not in excess of and thus capped by the otherwise undiscounted amount of the convertible notes. During the three months ended November 30, 2022, the Company amortized $ 1,490,513 2,750,917 During the three month period ended November 30, 2022, the Company made cash payments in the aggregate amount of $ 2,936,019 2,777,778 158,241 During the three months ended November 30, 2022, an aggregate of $ nil nil In connection with the $16.66m+ convertible notes, the Company is subject to certain financial covenants which the Company was not in compliance with as of November 30, 2022. This provided the lender the right to increase the interest rate to 15 Terragenx On November 17, 2021, Terragenx, a 91 1,875,000 937,500 1 May 17, 2022 948,874 November 29, 2022 946,875 1 The $1.875m convertible notes are secured by all assets of the Company. The $1.875m convertible notes are convertible at the option of the note holders to convert into shares of the Company’s common stock at $ 3.35 In connection with the $1.875m convertible notes, the Company issued the note holders warrants to purchase a total of 223,880 3.35 November 17, 2024 51,240 ● Expected life of 3.0 ● Volatility of 300 ● Dividend yield of 0 ● Risk free interest rate of 0.85 The face amount of the $1.875m convertible notes of $ 1,875,000 1,579,176 295,824 295,824 375,000 90,000 760,824 On December 2, 2022, the Company made a partial payment of $ 200,000 746,875

Debentures, Related Parties

Debentures, Related Parties	3 Months Ended
	Nov. 30, 2022
Debt Disclosure [Abstract]
Debentures, Related Parties	Note 12 – Debentures, Related Parties On September 30, 2013, the Company issued five debentures totaling CAD$ 6,402,512 6,225,163 8 September 30, 2016 September 30, 2019 September 30, 2021 December 1, 2023 On January 31, 2018, the debenture holders converted 75 3,894,809 414,965 1,047,588 The per share price used for the conversion of each debenture was $ 4.11 On July 21, 2020, the Company made a partial repayment of a debenture due to a related party of $ 267,768 At November 30, 2022 and August 31, 2022, the amount of debentures outstanding was $ 918,439 946,250

Leases

Leases	3 Months Ended
	Nov. 30, 2022
Leases
Leases	Note 13 – Leases Operating leases The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company discounts lease payments based on an estimate of its incremental borrowing rate. The Company leases its corporate office space and certain facilities under long-term operating leases expiring through fiscal year 2028. The table below presents the lease related assets and liabilities recorded on the Company’s condensed consolidated balance sheets as of November 30, 2022 and August 31, 2022: Schedule of Lease Related Assets and Liabilities November 30, August 31, 2022 2022 Classification on Balance Sheet Assets Operating lease assets Operating lease right of use assets $ 2,423,519 $ 2,673,934 Total lease assets $ 2,423,519 $ 2,673,934 Liabilities Current liabilities Operating lease liability Current operating lease liability $ 521,358 $ 582,088 Noncurrent liabilities Operating lease liability Long-term operating lease liability 2,010,041 2,185,329 Total lease liability $ 2,531,399 $ 2,767,417 Future minimum operating lease payments are as follows: Schedule of Lease Obligations Twelve Months Ending November 30, 2023 $ 715,223 2024 571,627 2025 496,959 2026 512,890 2027 422,053 Thereafter 480,427 Total payments 3,199,179 Amount representing interest (667,780 ) Lease obligation, net 2,531,399 Less lease obligation, current portion (521,358 ) Lease obligation, long-term portion $ 2,010,041 During the three months ended November 30, 2022, the Company did not enter into any new lease obligation. The lease expense for the three months ended November 30, 2022 and 2021 was $ 209,846 216,905 202,465 207,683 3.95 8 Finance Leases The Company leases certain equipment under lease contracts that are accounted for as finance leases. If the contracts meet the criteria for a finance lease, the related equipment underlying the lease contract is capitalized and amortized over its estimated useful life. If the cost of the equipment is not available, the Company calculates the cost by taking the present value of the lease payments using an implicit borrowing rate of 5 The net book value of equipment under finance leases included in property and equipment on the accompanying condensed consolidated balance sheets at November 30, 2022 and August 31, 2022 is as follows: Schedule of Finance Leases November 30, August 31, 2022 2022 Cost $ 209,457 $ 209,457 Accumulated amortization (206,311 ) (192,347 ) Net book value $ 3,146 $ 17,110 Future minimum finance lease payments are as follows: Schedule of Future Minimum Lease Payments Twelve Months Ending November 30, 2023 $ 16,301 2024 2,272 Total payments 18,573 Amount representing interest (370 ) Lease obligation, net 18,203 Less lease obligation, current portion (8,737 ) Lease obligation, long-term portion $ 9,466

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Nov. 30, 2022
Equity [Abstract]
Stockholders’ Equity	Note 14 – Stockholders’ Equity Convertible Preferred Stock The Company has authorized 1,000,000 0.001 0 0 Common Stock The Company has authorized 499,000,000 0.001 39,890,811 31,180,603 During the three months ended November 30, 2022, the Company issued: ● 4,000,000 0.50 The Company sold an aggregate of 4,000,000 2,000,000 4,000,000 4,000,000 4,000,000 0.50 4,000,000 4,000,000 0.50 140,000 7.0 1,795,000 The total fair value of the 8,000,000 1,137,959 149.06 206.90 0 2.55 2.89 0.2956 3 5 ● 36,222 October 26, 2022 ● 2,916,667 November 15, 2022 ● 1,757,319 November 15, 2022 Common Stock to be Issued As of November 30, 2022, in connection with the acquisition of Acenzia, Terragenx, 1285 Canada, and Poling Taddeo Hovius Physiotherapy Professional Corp, the Company has allotted and is obligated to issue 4,113,411 Stock Options On September 8, 2015, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2015 Incentive Compensation Plan (the “2015 Plan”), which authorized the issuance of up to 500,000 498,750 On January 16, 2018, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2018 Incentive Compensation Plan (the “2018 Plan”). Under the 2018 Plan, 1,000,000 864,900 On February 9, 2021, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2021 Equity Incentive Plan (the “2021 Plan”). Under the 2021 Plan, a total of 4,500,000 the maximum aggregate number of shares that may be issued under the 2021 Plan is eligible to be cumulatively increased on January 1, 2022 and on each subsequent January 1 through and including January 1, 2023, by a number of shares equal to the smaller of (i) 3% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (ii) an amount determined by our Board of Directors. The Company chose not to cumulatively increase the shares authorized for issuance under the 2021 Plan effective January 1, 2023. As of November 30, 2022, the 2021 Plan had 3,754,665 The following is a summary of stock options activity: Schedule of Stock Option Activity Weighted Weighted Average Average Remaining Aggregate Options Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2022 2,164,235 2.15 2.53 $ 140,577 Granted - Forfeited - Exercised - Outstanding, November 30, 2022 2,164,235 2.17 2.23 $ - Exercisable, November 30, 2022 2,070,240 $ 2.21 2.14 $ - The exercise price for stock options outstanding at November 30, 2022: Schedule of Options Outstanding Outstanding Exercisable Number of Exercise Number of Exercise Options Price Options Price 227,155 $ 1.33 133,160 $ 1.33 992,000 1.60 992,000 1.60 48,000 1.87 48,000 1.87 775,000 3.00 775,000 3.00 72,600 3.80 72,600 3.80 10,000 5.00 10,000 5.00 39,480 1.90 39,480 1.90 2,164,235 2,070,240 No For options granted during the three months ended November 30, 2021 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $ 3.76 3.80 The fair value of the stock options is being amortized to stock option expense over the vesting period. The Company recorded stock option expense of $ 60,887 154,135 60,887 The assumptions used in calculating the fair value of options granted using the Black-Scholes option-pricing model for options granted are as follows for the options granted during the three months ended November 30, 2022 and 2021: Schedule of Fair Value of Options Granted by Using Valuation Assumptions 2022 2021 Risk-free interest rate 0.93 1.89 % 0.93 % Expected life of the options 2.5 2.5 Expected volatility 281 % 282 % Expected dividend yield 0 % 0 % Warrants The following is a summary of warrant activity: Schedule of Warrant Activity Weighted Weighted Average Average Remaining Aggregate Warrants Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2022 8,445,264 2.42 3.75 $ - Granted 8,000,000 0.10 Forfeited - Exercised (4,673,986 ) Outstanding, November 30, 2022 11,771,278 0.81 3.76 $ 1,483,425 Exercisable, November 30, 2022 11,771,278 $ 0.81 3.76 $ 1,483,425 The exercise price for warrants outstanding at November 30, 2022: Schedule of Exercise Price of Warrants Outstanding Outstanding and Exercisable Number of Exercise Warrants Price 1,159,348 $ 0.00 2,611,930 3.35 8,000,000 0.10 11,771,278

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Nov. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 15 – Commitments and Contingencies Litigation The Company is party to certain legal proceedings from time-to-time incidental to the conduct of its business. These proceedings could result in fines, penalties, compensatory or treble damages or non-monetary relief. The nature of legal proceedings is such that the Company cannot assure the outcome of any particular matter, and an unfavorable ruling or development could have a materially adverse effect on our condensed consolidated financial position, results of operations and cash flows in the period in which a ruling or settlement occurs. However, based on information available to the Company’s management to date, the Company’s management does not expect that the outcome of any matter pending against the Company is likely to have a materially adverse effect on the Company’s unaudited condensed consolidated financial position as of November 30, 2022, results of operations, cash flows or liquidity of the Company.

Segment Reporting

Segment Reporting	3 Months Ended
	Nov. 30, 2022
Segment Reporting [Abstract]
Segment Reporting	Note 16 – Segment Reporting ASC Topic 280, Segment Reporting The following tables summarize the Company’s segment information for the three months ended November 30, 2022 and 2021: Schedule of Segment Reporting Information 2022 2021 Three Months Ended November 30, 2022 2021 Sales Healthcare services $ 2,021,213 $ 2,179,623 Product manufacturing and development 790,478 982,304 Corporate 607,589 - Sales $ 3,419,280 $ 3,161,927 Gross profit Healthcare services $ 784,031 $ 799,642 Product manufacturing and development 347,914 466,824 Corporate 607,588 - Gross profit $ 1,739,533 $ 1,266,466 Income (Loss) from operations Healthcare services $ (151,691 ) $ (111,105 ) Product manufacturing and development (554,842 ) (341,545 ) Corporate (1,535,427 ) (911,009 ) Loss from operations $ (2,241,960 ) $ (1,363,659 ) Depreciation and amortization Healthcare services $ 28,968 $ 74,606 Product manufacturing and development 309,042 252,076 Corporate 248,156 367,600 Depreciation and amortization $ 586,166 $ 694,282 Capital expenditures Healthcare services $ - $ 104,842 Product manufacturing and development - 15,555 Corporate - - Capital expenditures $ - $ 120,397 Interest expenses Healthcare services $ 36,303 $ 20,127 Product manufacturing and development 2,464 48,603 Corporate 128,476 - Interest expenses $ 167,243 $ 68,730 Net loss Healthcare services $ (185,713 ) $ (128,807 ) Product manufacturing and development (578,576 ) (782,542 ) Corporate (3,172,447 ) (905,046 ) Net loss $ (3,936,736 ) $ (1,816,395 ) As of As of November 30, August 31, 2022 2022 Total assets Healthcare services $ 5,662,841 $ 5,917,403 Product sales 18,483,229 19,595,269 Corporate 13,602,753 15,360,168 $ 37,748,823 $ 40,872,840 Accounts receivable Healthcare services $ 637,434 $ 585,492 Product sales 322,657 419,417 Corporate - 12,496 $ 960,091 $ 1,017,405 Intangible assets Healthcare services $ 146,169 $ 159,453 Product sales 4,443,751 5,283,333 Corporate 13,118,390 13,397,832 $ 17,708,310 $ 18,840,619 Goodwill Healthcare services $ 521,740 $ 537,537 Product sales 7,074,104 7,288,307 Corporate - - $ 7,595,844 $ 7,825,844

Subsequent Events

Subsequent Events	3 Months Ended
	Nov. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 17 – Subsequent Events Share Issuances in Connection with Warrant Exercises Subsequent to the period ended November 30, 2022, the Company issued an aggregate of 3,910,000 Share Issuances in Connection with Note Conversions Subsequent to the period ended November 30, 2022, the Company issued an aggregate of 94,185,340 0 0 0 Share Issuance in Exchange for Certain NHL Non-Voting Special Shares Subsequent to the period ended November 30, 2022, the Company issued 3,202,019 Nasdaq Notification—Minimum Bid Price Requirement On November 21, 2022, the Company received a notification letter (the “November Notification Letter”) from The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $ 1.00 The November Notification Letter provides that the Company has 180 calendar days, or until May 22, 2023, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company’s common stock must have a closing bid price of at least $ 1.00 The Company intends to monitor the closing bid price of its common stock and will consider implementing available options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules. Information Statement on Schedule 14C On January 4, 2023, the Company filed with the SEC a definitive information statement on Schedule 14C (the “14C”). The 14C relates to the notice to stockholders concerning the approval by written consent of stockholders holding a majority of the Company’s issued and outstanding voting securities (the “Majority Stockholders”) of the effectuation of the transactions provided for in each exchange offer and amendment entered into on November 14, 2022 by the Company (the “Exchange Offers and Amendments”) with CVI and Hudson Bay, including but not limited to the following amendments to the senior secured convertible notes, dated as of December 14, 2021, issued by the Company to CVI and Hudson (the “Notes”): (i) the definition of Conversion Price (as defined in the Notes) (the “Conversion Price”) shall be amended such that, as to the first $ 1,000,000 82.0 1,000,000 (ii) Each of the holders of the Notes may accelerate up to four Amortization Redemption Amounts (as defined in the Notes) provided that such holder agrees to accept shares of Common Stock instead of cash for such payments at a price per share equal to the Adjusted Conversion Price as calculated on the immediately preceding Amortization Date (as defined in the Notes)); and (iii) upon mutual consent by the Company and each of the holders of the Notes, such holder may elect to utilize the Adjusted Conversion Price for the balance of the Notes. Accordingly, the Majority Stockholders approved, by written consent, the issuance of the total number of shares of Company common stock of the Company necessary to effectuate the Exchange Offers and Amendments, which is currently an indeterminate number due to the methodology of the conversion pricing as described herein and in the Exchange Offers and Amendments. Stockholder approval of the Exchange Offers and Amendments was required by Rule 5635(d) of The Nasdaq Stock Market, which requires stockholder approval prior to a 20% issuance of securities at a price that is less than the Minimum Price (as defined in the information statement) in a transaction other than a public offering. A 20% issuance is a transaction, other than a public offering, involving the sale, issuance or potential issuance by the company of common stock (or securities convertible into or exercisable for common stock), which alone or together with sales by officers, directors or substantial stockholders of the company, equals 20% or more of the common stock or 20% or more of the voting power outstanding before the issuance. Such approval and consent by the Majority Stockholders constitute the approval and consent of a majority of the total number of shares of the Company’s outstanding voting stock and is sufficient under the Nevada Revised Statutes, the Company’s Amended and Restated Articles of Incorporation, as amended, and the Company’s Bylaws to approve the Exchange Offers and Amendments. Accordingly, the actions will not be submitted to the other stockholders of the Company for a vote, and the information statement has been furnished to such other stockholders to provide them with certain information concerning the actions in accordance with the requirements of the Exchange Act, and the regulations promulgated under the Exchange Act, including Regulation 14C. As of May 24, 2023, (i) the principal balance owed by the Company to Hudson Bay pursuant to the senior secured convertible note, dated as of December 14, 2021, as amended, issued by the Company to Hudson Bay is $ 0 0 Jefferson Street Letter Agreement As previously disclosed, on June 1, 2022, the Company and Jefferson agreed to extend the maturity date of the Jefferson Note to November 29, 2022 946,875 1 200,000 746,875 Nasdaq Notification—Delinquent Form 10-K and Form 10-Q Filings On December 15, 2022, the Company received a notification letter (the “December Notification Letter”) from Nasdaq that it was not in compliance with Nasdaq’s continued listing rules due to its failure to timely file its Annual Report on Form 10-K for the fiscal year ended August 31, 2022 (the “2022 10-K”). On January 25, 2023, the Company received a notification letter (the “January Notification Letter”) from Nasdaq advising the Company that it was not in compliance with Nasdaq’s continued listing requirements as a result of its failure to timely file the 2022 10-K and its Quarterly Report on Form 10-Q for the fiscal quarter ended November 30, 2022 (the “Form 10-Q”). On February 13, 2023, the Company submitted a plan to regain compliance with Nasdaq’s continued listing rules with respect to the 2022 10-K and the Form 10-Q. If Nasdaq accepted the Company’s plan, then Nasdaq could grant an exception of up to 180 calendar days from the due date of the 2022 10-K to regain compliance. On February 17, 2023 and March 22, 2023, based on Nasdaq’s further review, Nasdaq granted an exception to enable the Company to regain compliance with the Nasdaq’s continued listing rules. The terms of the exception are as follows: on or before May 29, 2023, the Company must file the 2022 10-K, the Form 10-Q, and any other filings required by Nasdaq Listing Rule 5250(c)(1). The Company filed the 2022 10-K on April 3, 2023. SwagCheck Agreement On December 23, 2022, the Company, SwagCheck Inc. (“SWAG”), and all SWAG shareholders (collectively, the “SWAG Shareholders”) entered into that certain Share Purchase Agreement (the “SWAG Agreement”). Pursuant to the terms of the SWAG Agreement, the Company agreed to purchase, and the SWAG Shareholders agreed to sell to the Company, 100 1.00 The parties have made customary representations, warranties and covenants in the SWAG Agreement. In addition to certain customary closing conditions, the obligations of SWAG and the SWAG Shareholders to consummate the closing of the SWAG Purchase are subject to the satisfaction (or waiver by any of SWAG or the SWAG Shareholders), at or before the closing date, of certain conditions, including that (i) the Company will have received a financing commitment of at least $ 90 60 30 In addition to certain customary closing conditions in the SWAG Agreement, the obligations of SWAG and the SWAG Shareholders to consummate the closing of the SWAG Purchase were subject to the satisfaction (or waiver by any of SWAG or the SWAG Shareholders), at or before the closing date, of certain conditions, including that (i) the Company will have provided SWAG with a binding letter of intent (a “LOI”) by a competent financing party for financing in the amount of at least $ 90 60 30 On December 30, 2022, the Company, SWAG and the SWAG Shareholders entered into Amendment No. 1 to the SWAG Agreement (the “SWAG Amendment”). Pursuant to the terms of the SWAG Amendment, the parties agreed as follows: ● The closing of the SWAG Purchase will occur no later than January 10, 2023, with all contemplated extensions being subject to the Receiver’s stipulations, conditions, and limitations. ● The condition for the Company to provide SWAG with a binding LOI has been deleted. ● A total of $ 92 60 32 Although the SWAG Agreement has not yet closed, the parties continue to work together with the intention of closing the transaction. Following the closing of SWAG Purchase, SWAG will be a wholly owned subsidiary of the Company and will own title to the Gems, which the Company intends to either collateralize or sell to raise capital. Mast Hill Securities Purchase Agreement & Note On February 23, 2023, the Company entered into a securities purchase agreement (the “Mast Hill SPA”) with Mast Hill Fund, L.P. (“Mast Hill”), pursuant to which the Company issued an 12 February 23, 2024 573,000 1,000,000 12 57,300 515,700 0.175 Pursuant to the terms of the Mast Hill Note, the Company agreed to pay accrued interest monthly as well as the Mast Hill Principal Sum as follows: (i) $ 57,300 57,300 57,300 100,000 100,000 100,000 85 The Company may prepay the Mast Hill Note at any time prior to the date that an Event of Default (as defined in the Mast Hill Note) occurs at an amount equal to the Mast Hill Principal Sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $ 750 Upon the occurrence of any Event of Default, the Mast Hill Note shall become immediately due and payable and the Company shall pay to Mast Hill, in full satisfaction of its obligations hereunder, an amount equal to the Mast Hill Principal Sum then outstanding plus accrued interest multiplied by 125 16 The Mast Hill Warrant is exercisable for five years from February 23, 2023, at an exercise price of $ 0.25 As additional consideration for the purchase of the Mast Hill Note and pursuant to the terms of the Mast Hill SPA, on February 24, 2023, the Company issued 955,000 19.99 27,720,448 On March 23, 2023, the Company made a monthly interest-only payment to Mast Hill in the amount of $ 5,086 5,840 March 2023 FirstFire Securities Purchase Agreement, Note & Warrant On March 21, 2023, the Company entered into a securities purchase agreement (the “SPA”) with FirstFire, pursuant to which the Company issued an 12 March 21, 2024 573,000 1,000,000 12 57,300 515,700 0.175 Pursuant to the terms of the 2023 FirstFire Note, the Company agreed to pay accrued interest monthly as well as the Principal Sum as follows: (i) $ 57,300 57,300 57,300 100,000 100,000 100,000 85 The Company may prepay the 2023 FirstFire Note at any time prior to the date that an event of default (as provided in the 2023 FirstFire Note) occurs at an amount equal to the Principal Sum then outstanding plus accrued and unpaid interest (no prepayment premium) plus $ 750 Upon the occurrence of any event of default, the 2023 FirstFire Note shall become immediately due and payable and the Company shall pay to FirstFire, in full satisfaction of its obligations hereunder, an amount equal to the Principal Sum then outstanding plus accrued interest multiplied by 125 16 The 2023 FirstFire Warrant is exercisable for five years from March 21, 2023, at an exercise price of $ 0.25 As additional consideration for the purchase of the 2023 FirstFire Note and pursuant to the terms of the SPA, on March 22, 2023, the Company issued 955,000 10,000,000 On April 21, 2023, the company made a monthly interest-only payment to FirstFire in the amount of $ 5,730 RC Consulting Group SPA & Unsecured $70 Million Note On April 26, 2023, the Company entered into a securities purchase agreement (the “RC SPA”), dated as of April 26, 2023, with RC Consulting Group LLC in favor of SCP Tourbillion Monaco or registered assigns (the “RC Noteholder”), pursuant to which the Company issued an unsecured 15-year promissory note to the RC Noteholder (the “RC Note”) with a maturity date of April 26, 2038 70,000,000 57,000,000 1.52 Pursuant to the terms of the RC Note, at the RC Noteholder’s option, the sale, conveyance or disposition of all or substantially all of the Company’s assets, or the consolidation, merger or other business combination of the Company with or into any other person(s) when the Company is not the survivor will either: (i) be deemed to be an Event of Default (as defined in the RC Note) pursuant to which the Company will be required to pay to the RC Noteholder upon the consummation of and as a condition to such transaction an amount equal to the Default Amount (as hereinafter defined), or (ii) be treated pursuant to Section 1.6(b) of the RC Note. The RC Note contains customary covenants for a transaction of this type. Among other things, so long as the RC Note is outstanding, the Company will not enter into any transaction or arrangement structured in accordance with, based upon, or related or pursuant to, in whole or in part, Section 3(a)(10) of the Securities Act of 1933, as amended (a “3(a)(10) Transaction”). In the event that the Company does enter into, or makes any issuance of common stock related to a 3(a)(10) Transaction while the RC Note is outstanding, a liquidated damages charge of 25% of the outstanding principal balance of the RC Note, but not less than $1,000,000, will be assessed and will become immediately due and payable to the RC Noteholder at its election in the form of a cash payment or added to the balance of the RC Note (under the RC Noteholder’s and the Company’s expectation that this amount will tack back to the date of issuance of the RC Note). The RC Note contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties, and breach of provisions of the RC SPA or the RC Note. Upon the occurrence of any Event of Default (as defined in the RC Note), the RC Note will become immediately due and payable, and the Company will pay to the RC Noteholder, in full satisfaction of its obligations thereunder, an amount equal to the principal amount then outstanding plus accrued interest (including any default interest) through the date of full repayment multiplied by 125 The RC SPA contains customary covenants, representations and warranties for a transaction of this type.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Nov. 30, 2022
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to going concern assessment, useful lives of non-current assets, impairment of non-current assets, allowance for doubtful receivables, allowance for slow moving and obsolete inventory, valuation of share-based compensation and warrants, and valuation allowance for deferred tax assets. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and entities it controls including its wholly owned subsidiaries, NHL, Acenzia Inc. (“Acenzia”), Novomerica Health Group, Inc. (“NHG”), Novo Healthnet Rehab Limited, Novo Assessments Inc., PRO-DIP, LLC (“PRO-DIP”), a 91 50.1 80 70 All intercompany transactions have been eliminated. An entity is controlled when the Company has the ability to direct the relevant activities of the entity, has exposure or rights to variable returns from its involvement with the entity, and is able to use its power over the entity to affect its returns from the entity. Income or loss and each component of other comprehensive income (“OCI”) are attributed to the shareholders of the Company and to the noncontrolling interests. Total comprehensive loss is attributed to the shareholders of the Company and to the noncontrolling interests even if this results in the non-controlling interests having a deficit balance on consolidation.
Noncontrolling Interest	Noncontrolling Interest The Company follows FASB ASC Topic 810, Consolidation, The net income (loss) attributed to the NCI is separately designated in the accompanying condensed consolidated statements of operations and comprehensive loss.
Cash Equivalents	Cash Equivalents For the purpose of the condensed consolidated statements of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of November 30, 2022 and August 31, 2022, the allowance for uncollectible accounts receivable was $ 957,375 992,329
Inventory	Inventory Inventories are valued at the lower of cost (determined by the first in, first out method) and net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. Inventory is segregated into three areas: raw materials, work-in-process and finished goods. The Company periodically assessed its inventory for slow moving and/or obsolete items and any change in the allowance is recorded in cost of revenues in the accompanying condensed consolidated statements of operations and comprehensive loss. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired. As of November 30, 2022 and August 31, 2022, the Company’s allowance for slow moving or obsolete inventory was $ 997,467 1,027,670
Other Receivables	Other Receivables Other receivables are recorded at cost and presented as current or long-term based on the terms of the agreements. Management reviews the collectability of other receivables and writes off the portion that is deemed to be uncollectible. During the period/year ended November 30, 2022 and August 31, 2022, the Company wrote off $ nil 299,672 225,924 73,748
Property and Equipment	Property and Equipment Property and equipment are stated at cost less depreciation and impairment. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows: Schedule of Estimated Useful Lives of Assets Building 30 Leasehold improvements 5 Clinical equipment 5 Computer equipment 3 Office equipment 5 Furniture and fixtures 5
Leases	Leases The Company applies the provisions of ASC Topic 842, Leases
Long-Lived Assets	Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment no
Intangible Assets	Intangible Assets The Company’s intangible assets are being amortized over their estimated useful lives as follows: Schedule of Intangible Assets Amortized Estimated Useful Lives Land use rights 50 Intellectual property 7 Customer relationships 5 Brand names 7 The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Based on its reviews at November 30, 2022, the Company believes there was no impairment of its intangible assets.
Right-of-use Assets	Right-of-use Assets The Company’s right-of-use assets consist of leased assets recognized in accordance with ASC 842, Leases, which 12 months
Goodwil	Goodwil Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under U.S. GAAP, goodwill is not amortized but is subject to annual impairment tests. The Company recorded goodwill related to its acquisition of APKA Health, Inc. (“APKA”) during the fiscal year ended August 31, 2017, Executive Fitness Leaders (“EFL”) during the fiscal year ended August 31, 2018, Action Plus Physiotherapy Rockland (“Rockland”) during the fiscal year ended August 31, 2019, Acenzia during the fiscal year ended August 31, 2021, and 1285 Canada during the fiscal year ended August 31, 2022. As of August 31, 2022, the Company performed the required impairment reviews and determined that an impairment charge of $ 1,357,043 Summary of changes in goodwill by acquired businesses is as follows: Schedule of Changes in Goodwill APKA EFL Rockland Acenzia 1285 Canada Total Balance, August 31, 2021 $ 197,925 $ 129,839 $ 229,593 $ 8,931,491 $ - $ 9,488,848 Goodwill acquired with purchase of business - - - - 602 602 Impairment of goodwill - - - (1,357,043 ) - (1,357,043 ) Foreign currency translation adjustment (7,247 ) (4,751 ) (8,405 ) (286,141 ) (19 ) (306,563 ) Balance, August 31, 2022 $ 190,678 $ 125,088 $ 221,188 $ 7,288,307 $ 583 $ 7,825,844 Beginning balance $ 190,678 $ 125,088 $ 221,188 $ 7,288,307 $ 583 $ 7,825,844 Foreign currency translation adjustment (5,600 ) (3,673 ) (6,507 ) (214,203 ) (17 ) (230,000 ) Balance, November 30, 2022 $ 185,078 $ 121,415 $ 214,681 $ 7,074,104 $ 566 $ 7,595,844 Ending balance $ 185,078 $ 121,415 $ 214,681 $ 7,074,104 $ 566 $ 7,595,844
Fair Value of Financial Instruments	Fair Value of Financial Instruments For certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, other receivables, accounts payable, accrued expenses, current portion of finance and operating lease liability, and due to related parties, the carrying amounts approximate their fair values due to their short-term maturities. FASB ASC Topic 820, Fair Value Measurements and Disclosures Financial Instruments ● Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement. The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity Derivatives and Hedging For certain financial instruments, the carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, other receivables, and current liabilities, including accounts payable, short-term notes payable, due to related parties, operating lease liability and finance lease liability, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The carrying value of notes payable approximates their fair values due to current market rate on such debt. As of November 30, 2022 and August 31, 2022, respectively, the Company did not identify any financial assets and liabilities required to be presented on the condensed consolidated balance sheet at fair value, except for cash and cash equivalents which are carried at fair value using Level 1 inputs and derivative liability which is carried at fair value using level 3 inputs.
Derivative Financial Instruments	Derivative Financial Instruments Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments and measurement of their fair value for accounting purposes. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt under ASC 470, the Company will continue its evaluation process of these instruments as derivative financial instruments under ASC 815. The Company applies the guidance in ASC 815-40-35-12 to determine the order in which each convertible instrument would be evaluated for derivative classification. Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to the fair value of derivatives.
Revenue Recognition	Revenue Recognition The Company’s revenue recognition reflects the updated accounting policies as per the requirements of FASB Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers Revenue from providing healthcare and healthcare related services and product sales are recognized under Topic 606 ● executed contracts with the Company’s customers that it believes are legally enforceable; ● identification of performance obligations in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. These five elements, as applied to the Company’s revenue category, are summarized below: ● Healthcare and healthcare related services – gross service revenue is recorded in the accounting records at the time the services are provided (point-in-time) on an accrual basis at the provider’s established rates. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes. ● Product sales – revenue is recorded at the point of time of delivery In arrangements where another party is involved in providing specified services to a customer, the Company evaluates whether it is the principal or agent. In this evaluation, the Company considers if the Company obtains control of the specified goods or services before they are transferred to the customer, as well as other indicators such as the party primarily responsible for fulfillment, inventory risk, and discretion in establishing price. For product sales where the Company is not the principal, the Company recognizes revenue on a net basis. For the periods presented, revenue for arrangements where the Company is the agent was not material. Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue. Unearned revenue is included with accrued expenses in the accompanying condensed consolidated balance sheets. Sales returns and allowances were insignificant for the periods ended November 30, 2022 and 2021. The Company does not provide unconditional right of return, price protection or any other concessions to its customers.
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.
Stock-Based Compensation	Stock-Based Compensation The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation
Basic and Diluted Earnings Per Share	Basic and Diluted Earnings Per Share Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share 18,609,499 4,509,530 4,441,359 4,113,411 Due to the net loss incurred potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss per share for all periods presented.
Foreign Currency Transactions and Comprehensive Income	Foreign Currency Transactions and Comprehensive Income U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the CAD and the functional currency of the parent company is the United States dollar. Translation losses of $ 420,982 431,605
Statement of Cash Flows	Statement of Cash Flows Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the condensed consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the condensed consolidated balance sheets.
Segment Reporting	Segment Reporting ASC Topic 280, Segment Reporting
Reclassifications	Reclassifications Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or shareholders’ equity.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying condensed consolidated financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Organization and Basis of Pre_2

Organization and Basis of Presentation (Tables)	3 Months Ended
	Nov. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Foreign Currency Translation, Exchange Rate Used	Schedule of Foreign Currency Translation, Exchange Rate Used November 30, 2022 November 30, 2021 August 31, 2022 Period end: CAD to USD exchange rate $ 0.7403 $ 0.7807 $ 0.7627 Average period: CAD to USD exchange rate $ 0.7414 $ 0.7961 $ 0.7864

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Nov. 30, 2022
Accounting Policies [Abstract]
Schedule of Estimated Useful Lives of Assets	Schedule of Estimated Useful Lives of Assets Building 30 Leasehold improvements 5 Clinical equipment 5 Computer equipment 3 Office equipment 5 Furniture and fixtures 5
Schedule of Intangible Assets Amortized Estimated Useful Lives	The Company’s intangible assets are being amortized over their estimated useful lives as follows: Schedule of Intangible Assets Amortized Estimated Useful Lives Land use rights 50 Intellectual property 7 Customer relationships 5 Brand names 7
Schedule of Changes in Goodwill	Summary of changes in goodwill by acquired businesses is as follows: Schedule of Changes in Goodwill APKA EFL Rockland Acenzia 1285 Canada Total Balance, August 31, 2021 $ 197,925 $ 129,839 $ 229,593 $ 8,931,491 $ - $ 9,488,848 Goodwill acquired with purchase of business - - - - 602 602 Impairment of goodwill - - - (1,357,043 ) - (1,357,043 ) Foreign currency translation adjustment (7,247 ) (4,751 ) (8,405 ) (286,141 ) (19 ) (306,563 ) Balance, August 31, 2022 $ 190,678 $ 125,088 $ 221,188 $ 7,288,307 $ 583 $ 7,825,844 Beginning balance $ 190,678 $ 125,088 $ 221,188 $ 7,288,307 $ 583 $ 7,825,844 Foreign currency translation adjustment (5,600 ) (3,673 ) (6,507 ) (214,203 ) (17 ) (230,000 ) Balance, November 30, 2022 $ 185,078 $ 121,415 $ 214,681 $ 7,074,104 $ 566 $ 7,595,844 Ending balance $ 185,078 $ 121,415 $ 214,681 $ 7,074,104 $ 566 $ 7,595,844

Accounts Receivables, net (Tabl

Accounts Receivables, net (Tables)	3 Months Ended
	Nov. 30, 2022
Receivables [Abstract]
Schedule of Accounts Receivables, Net	Accounts receivables, net at November 30, 2022 and August 31, 2022 consisted of the following: Schedule of Accounts Receivables, Net November 30, August 31, 2022 2022 Trade receivables $ 1,828,732 $ 1,829,475 Amounts earned but not billed 88,734 180,259 Accounts receivable gross 1,917,466 2,009,734 Allowance for doubtful accounts (957,375 ) (992,329 ) Accounts receivable, net $ 960,091 $ 1,017,405

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Nov. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory at November 30, 2022 and August 31, 2022 consisted of the following: Schedule of Inventory November 30, August 31, 2022 2022 Raw materials $ 1,380,358 $ 1,259,954 Work in process 135,238 139,333 Finished Goods 491,986 507,416 Inventory Gross 2,007,582 1,906,703 Allowance for slow moving and obsolete inventory (997,467 ) (1,027,670 ) Inventory, net $ 1,010,115 $ 879,033

Other Receivables (Tables)

Other Receivables (Tables)	3 Months Ended
	Nov. 30, 2022
Receivables [Abstract]
Schedule of Other Receivables	Other receivables at November 30, 2022 and August 31, 2022 consisted of the following: Schedule of Other Receivables November 30, August 31, 2022 2022 - 74,030 76,272 Advance to corporation; accrues interest at 12 January 31, 2024 74,030 76,272 Advance to corporation; accrues interest at 12 September 1, 2023 535,327 551,536 Advance to corporation; accrues interest at 10 September 1, 2023 444,080 457,527 Total other receivables 1,053,437 1,085,335 Current portion (1,053,437 ) (1,085,335 ) Long-term portion $ - $ -

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Nov. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment at November 30, 2022 and August 31, 2022 consisted of the following: Schedule of Property and Equipment November 30, August 31, 2022 2022 Land $ 444,181 $ 457,631 Building 3,331,359 3,432,232 Leasehold improvements 842,853 868,375 Clinical equipment 1,870,986 1,927,639 Computer equipment 33,563 34,579 Office equipment 44,552 45,406 Furniture and fixtures 38,356 39,518 Property and equipment gross 6,605,850 6,805,380 Accumulated depreciation (1,042,021 ) (1,004,732 ) Total $ 5,563,829 $ 5,800,648

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Nov. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets at November 30, 2022 and August 31, 2022 consisted of the following: Schedule of Intangible Assets November 30, August 31, 2022 2022 Land use rights $ 11,573,321 $ 11,573,321 Intellectual property 7,503,709 8,059,386 Customer relationships 2,292,655 2,320,154 Brand names 1,931,818 1,990,314 Finite lived intangible assets, gross 23,301,503 23,943,175 Accumulated amortization (5,593,193 ) (5,102,556 ) Total $ 17,708,310 $ 18,840,619
Schedule of Expected Amortization Expense of Intangible Assets	Expected amortization expense of intangible assets over the next 5 years and thereafter is as follows: Schedule of Expected Amortization Expense of Intangible Assets Twelve Months Ending November 30, 2023 $ 2,002,793 2024 2,002,793 2025 1,819,531 2026 1,457,184 2027 1,206,276 Thereafter 9,219,733 Total $ 17,708,310

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Nov. 30, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses at November 30, 2022 and August 31, 2022 consisted of the following: Schedule of Accrued Expenses November 30, August 31, 2022 2022 Accrued liabilities $ 972,344 $ 884,024 Accrued payroll 224,394 195,214 Unearned revenue 35,781 36,887 Accrued expenses $ 1,232,519 $ 1,116,125

Government Loans and Notes Pa_2

Government Loans and Notes Payable (Tables)	3 Months Ended
	Nov. 30, 2022
Government Loans And Notes Payable
Schedule of Governmental Loans and Note Payable	Notes payable at November 30, 2022 and August 31, 2022 consisted of the following: Schedule of Governmental Loans and Note Payable November 30, August 31, 2022 2022 Government loans issued under the Government of Canada’s Canada Emergency Business Account (“CEBA”) program (A). 88,836 91,526 Note payable to the Small Business Administration (“SBA”). The note bears interest at 3.75 monthly 190 30 40,320 40,320 Note payable dated December 3, 2018; accrues interest at 4.53 annual 4,000 December 31, 2028 28,744 29,614 Total government loans and notes payable 157,900 161,460 Less current portion - - Long-term portion $ 157,900 $ 161,460 (A) The Government of Canada launched CEBA loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained CAD$ 80,000 59,224 December 31, 2023 If the loan amount is paid on or before December 31, 2023, 25 75 60,000 20,000 29,612
Schedule of Future Maturities Outstanding of Governmental Loans and Note Payable	Future scheduled maturities of outstanding government loans and notes payable are as follows: Schedule of Future Maturities Outstanding of Governmental Loans and Note Payable Twelve Months Ending November 30, 2023 $ 6,242 2024 95,079 2025 6,242 2026 6,242 2027 6,242 Thereafter 37,853 Total $ 157,900

Leases (Tables)

Leases (Tables)	3 Months Ended
	Nov. 30, 2022
Leases
Schedule of Lease Related Assets and Liabilities	The table below presents the lease related assets and liabilities recorded on the Company’s condensed consolidated balance sheets as of November 30, 2022 and August 31, 2022: Schedule of Lease Related Assets and Liabilities November 30, August 31, 2022 2022 Classification on Balance Sheet Assets Operating lease assets Operating lease right of use assets $ 2,423,519 $ 2,673,934 Total lease assets $ 2,423,519 $ 2,673,934 Liabilities Current liabilities Operating lease liability Current operating lease liability $ 521,358 $ 582,088 Noncurrent liabilities Operating lease liability Long-term operating lease liability 2,010,041 2,185,329 Total lease liability $ 2,531,399 $ 2,767,417
Schedule of Lease Obligations	Future minimum operating lease payments are as follows: Schedule of Lease Obligations Twelve Months Ending November 30, 2023 $ 715,223 2024 571,627 2025 496,959 2026 512,890 2027 422,053 Thereafter 480,427 Total payments 3,199,179 Amount representing interest (667,780 ) Lease obligation, net 2,531,399 Less lease obligation, current portion (521,358 ) Lease obligation, long-term portion $ 2,010,041
Schedule of Finance Leases	The net book value of equipment under finance leases included in property and equipment on the accompanying condensed consolidated balance sheets at November 30, 2022 and August 31, 2022 is as follows: Schedule of Finance Leases November 30, August 31, 2022 2022 Cost $ 209,457 $ 209,457 Accumulated amortization (206,311 ) (192,347 ) Net book value $ 3,146 $ 17,110
Schedule of Future Minimum Lease Payments	Future minimum finance lease payments are as follows: Schedule of Future Minimum Lease Payments Twelve Months Ending November 30, 2023 $ 16,301 2024 2,272 Total payments 18,573 Amount representing interest (370 ) Lease obligation, net 18,203 Less lease obligation, current portion (8,737 ) Lease obligation, long-term portion $ 9,466

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	3 Months Ended
	Nov. 30, 2022
Equity [Abstract]
Schedule of Stock Option Activity	The following is a summary of stock options activity: Schedule of Stock Option Activity Weighted Weighted Average Average Remaining Aggregate Options Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2022 2,164,235 2.15 2.53 $ 140,577 Granted - Forfeited - Exercised - Outstanding, November 30, 2022 2,164,235 2.17 2.23 $ - Exercisable, November 30, 2022 2,070,240 $ 2.21 2.14 $ -
Schedule of Options Outstanding	The exercise price for stock options outstanding at November 30, 2022: Schedule of Options Outstanding Outstanding Exercisable Number of Exercise Number of Exercise Options Price Options Price 227,155 $ 1.33 133,160 $ 1.33 992,000 1.60 992,000 1.60 48,000 1.87 48,000 1.87 775,000 3.00 775,000 3.00 72,600 3.80 72,600 3.80 10,000 5.00 10,000 5.00 39,480 1.90 39,480 1.90 2,164,235 2,070,240
Schedule of Fair Value of Options Granted by Using Valuation Assumptions	The assumptions used in calculating the fair value of options granted using the Black-Scholes option-pricing model for options granted are as follows for the options granted during the three months ended November 30, 2022 and 2021: Schedule of Fair Value of Options Granted by Using Valuation Assumptions 2022 2021 Risk-free interest rate 0.93 1.89 % 0.93 % Expected life of the options 2.5 2.5 Expected volatility 281 % 282 % Expected dividend yield 0 % 0 %
Schedule of Warrant Activity	The following is a summary of warrant activity: Schedule of Warrant Activity Weighted Weighted Average Average Remaining Aggregate Warrants Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2022 8,445,264 2.42 3.75 $ - Granted 8,000,000 0.10 Forfeited - Exercised (4,673,986 ) Outstanding, November 30, 2022 11,771,278 0.81 3.76 $ 1,483,425 Exercisable, November 30, 2022 11,771,278 $ 0.81 3.76 $ 1,483,425
Schedule of Exercise Price of Warrants Outstanding	The exercise price for warrants outstanding at November 30, 2022: Schedule of Exercise Price of Warrants Outstanding Outstanding and Exercisable Number of Exercise Warrants Price 1,159,348 $ 0.00 2,611,930 3.35 8,000,000 0.10 11,771,278

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Nov. 30, 2022
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	The following tables summarize the Company’s segment information for the three months ended November 30, 2022 and 2021: Schedule of Segment Reporting Information 2022 2021 Three Months Ended November 30, 2022 2021 Sales Healthcare services $ 2,021,213 $ 2,179,623 Product manufacturing and development 790,478 982,304 Corporate 607,589 - Sales $ 3,419,280 $ 3,161,927 Gross profit Healthcare services $ 784,031 $ 799,642 Product manufacturing and development 347,914 466,824 Corporate 607,588 - Gross profit $ 1,739,533 $ 1,266,466 Income (Loss) from operations Healthcare services $ (151,691 ) $ (111,105 ) Product manufacturing and development (554,842 ) (341,545 ) Corporate (1,535,427 ) (911,009 ) Loss from operations $ (2,241,960 ) $ (1,363,659 ) Depreciation and amortization Healthcare services $ 28,968 $ 74,606 Product manufacturing and development 309,042 252,076 Corporate 248,156 367,600 Depreciation and amortization $ 586,166 $ 694,282 Capital expenditures Healthcare services $ - $ 104,842 Product manufacturing and development - 15,555 Corporate - - Capital expenditures $ - $ 120,397 Interest expenses Healthcare services $ 36,303 $ 20,127 Product manufacturing and development 2,464 48,603 Corporate 128,476 - Interest expenses $ 167,243 $ 68,730 Net loss Healthcare services $ (185,713 ) $ (128,807 ) Product manufacturing and development (578,576 ) (782,542 ) Corporate (3,172,447 ) (905,046 ) Net loss $ (3,936,736 ) $ (1,816,395 ) As of As of November 30, August 31, 2022 2022 Total assets Healthcare services $ 5,662,841 $ 5,917,403 Product sales 18,483,229 19,595,269 Corporate 13,602,753 15,360,168 $ 37,748,823 $ 40,872,840 Accounts receivable Healthcare services $ 637,434 $ 585,492 Product sales 322,657 419,417 Corporate - 12,496 $ 960,091 $ 1,017,405 Intangible assets Healthcare services $ 146,169 $ 159,453 Product sales 4,443,751 5,283,333 Corporate 13,118,390 13,397,832 $ 17,708,310 $ 18,840,619 Goodwill Healthcare services $ 521,740 $ 537,537 Product sales 7,074,104 7,288,307 Corporate - - $ 7,595,844 $ 7,825,844

Schedule of Foreign Currency Tr

Schedule of Foreign Currency Translation, Exchange Rate Used (Details)	Nov. 30, 2022	Aug. 31, 2022	Nov. 30, 2021
Period End [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Foreign currency exchange rate	0.7403	0.7627	0.7807
Average Period [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Foreign currency exchange rate	0.7414	0.7864	0.7961

Organization and Basis of Pre_3

Organization and Basis of Presentation (Details Narrative) - USD ($)				3 Months Ended
	Feb. 01, 2021	May 09, 2017	Apr. 25, 2017	Nov. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reverse stock split	the Company effected a 1-for-10 reverse stock split of our common stock. As a result of the reverse stock split, every 10 shares of issued and outstanding common stock were exchanged for one share of common stock, with any fractional shares being rounded up to the next higher whole share. Unless otherwise noted, the share and per share information in this report have been retroactively adjusted to give effect to the 1-for-10 reverse stock split
Parent Company [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock issued in connection with reverse merger transaction		$ 6,904
Share Exchange Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of restricted shares of common stock, shares				36,222
Share Exchange Agreement [Member] | NHL [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of restricted shares of common stock, shares			16,779,741
Percentage of common stock issued and outstanding			85%

Schedule of Estimated Useful Li

Schedule of Estimated Useful Lives of Assets (Details)	3 Months Ended
	Nov. 30, 2022
Building [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	30 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years
Clinical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	3 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years

Schedule of Intangible Assets A

Schedule of Intangible Assets Amortized Estimated Useful Lives (Details)	3 Months Ended
	Nov. 30, 2022
Land Use Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	50 years
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	7 years
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	5 years
Brand Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	7 years

Schedule of Changes in Goodwill

Schedule of Changes in Goodwill (Details) - USD ($)	3 Months Ended	12 Months Ended
	Nov. 30, 2022	Aug. 31, 2022
Beginning balance	$ 7,825,844	$ 9,488,848
Goodwill acquired with purchase of business		602
Impairment of goodwill		(1,357,043)
Foreign currency translation adjustment	(230,000)	(306,563)
Ending balance	7,595,844	7,825,844
Apka Health Inc [Member]
Beginning balance	190,678	197,925
Goodwill acquired with purchase of business
Impairment of goodwill
Foreign currency translation adjustment	(5,600)	(7,247)
Ending balance	185,078	190,678
Executive Fitness Leaders [Member]
Beginning balance	125,088	129,839
Goodwill acquired with purchase of business
Impairment of goodwill
Foreign currency translation adjustment	(3,673)	(4,751)
Ending balance	121,415	125,088
Rockland [Member]
Beginning balance	221,188	229,593
Goodwill acquired with purchase of business
Impairment of goodwill
Foreign currency translation adjustment	(6,507)	(8,405)
Ending balance	214,681	221,188
Acenzia Inc [Member]
Beginning balance	7,288,307	8,931,491
Goodwill acquired with purchase of business
Impairment of goodwill		(1,357,043)
Foreign currency translation adjustment	(214,203)	(286,141)
Ending balance	7,074,104	7,288,307
1285 Canada Corp [Member]
Beginning balance	583
Goodwill acquired with purchase of business		602
Impairment of goodwill
Foreign currency translation adjustment	(17)	(19)
Ending balance	$ 566	$ 583

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Nov. 30, 2022	Nov. 30, 2021	Aug. 31, 2022	Nov. 17, 2021
Allowance for uncollectible accounts receivable	$ 957,375		$ 992,329
Inventory	997,467		1,027,670
Other receivable written off			299,672
Debt face amount			225,924	$ 1,875,000
Accrued interest			73,748
Impairment of long-lived assets	$ 0
Contract lease term	12 months
Goodwill impairment charge			1,357,043
Foreign currency translation gain (loss)	$ 420,982	$ 104,388	$ 431,605
Common Stock [Member]
Debt conversion, converted instrument, shares issued	4,441,359
Common Stock to be Issued [Member]
Debt conversion, converted instrument, shares issued	4,113,411
Options/Warrants Outstanding [Member]
Potentially dilutive common stock options and warrants outstanding, shares	18,609,499	4,509,530
Terragenx [Member]
Equity method investment, ownership percentage			91%
1285 Canada Corp [Member]
Equity method investment, ownership percentage			50.10%
Novo Healthnet Kemptville Centre Inc [Member]
Equity method investment, ownership percentage			80%
Novo Earth Therapeutics Inc [Member]
Equity method investment, ownership percentage			70%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Nov. 30, 2022	Aug. 31, 2022
Short-Term Debt [Line Items]
Due to related parties	$ 417,718	$ 478,897
Non-Interest Bearing [Member]
Short-Term Debt [Line Items]
Due to related parties	335,710	394,405
6% Interest Rate [Member]
Short-Term Debt [Line Items]
Due to related parties	$ 21,304	$ 21,949
Bearing interest rate	6%	6%
13.75% Interest Rate [Member]
Short-Term Debt [Line Items]
Due to related parties	$ 60,704	$ 62,543
Bearing interest rate	13.75%	13.75%

Schedule of Accounts Receivable

Schedule of Accounts Receivables, Net (Details) - USD ($)	Nov. 30, 2022	Aug. 31, 2022
Receivables [Abstract]
Trade receivables	$ 1,828,732	$ 1,829,475
Amounts earned but not billed	88,734	180,259
Accounts receivable gross	1,917,466	2,009,734
Allowance for doubtful accounts	(957,375)	(992,329)
Accounts receivable, net	$ 960,091	$ 1,017,405

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($)	Nov. 30, 2022	Aug. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 1,380,358	$ 1,259,954
Work in process	135,238	139,333
Finished Goods	491,986	507,416
Inventory Gross	2,007,582	1,906,703
Allowance for slow moving and obsolete inventory	(997,467)	(1,027,670)
Inventory, net	$ 1,010,115	$ 879,033

Schedule of Other Receivables (

Schedule of Other Receivables (Details) - USD ($)	Nov. 30, 2022	Aug. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	$ 1,053,437	$ 1,085,335
Current portion	(1,053,437)	(1,085,335)
Long-term portion
Advance to Corporation One [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	74,030	76,272
Advance to Corporation Two [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	535,327	551,536
Advance to Corporation Three [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	$ 444,080	$ 457,527

Schedule of Other Receivables_2

Schedule of Other Receivables (Details) (Parenthetical)	3 Months Ended	12 Months Ended
	Nov. 30, 2022	Aug. 31, 2022
Advance to Corporation One [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of interest accrued per annum	12%	12%
Notes receivable due date	Jan. 31, 2024	Jan. 31, 2024
Advance to Corporation Two [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of interest accrued per annum	12%	12%
Notes receivable due date	Sep. 01, 2023	Sep. 01, 2023
Advance to Corporation Three [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of interest accrued per annum	10%	10%
Notes receivable due date	Sep. 01, 2023	Sep. 01, 2023

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($)	Nov. 30, 2022	Aug. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 6,605,850	$ 6,805,380
Accumulated depreciation	(1,042,021)	(1,004,732)
Total	5,563,829	5,800,648
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	444,181	457,631
Building [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	3,331,359	3,432,232
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	842,853	868,375
Clinical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	1,870,986	1,927,639
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	33,563	34,579
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	44,552	45,406
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 38,356	$ 39,518

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 60,043	$ 74,606

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($)	Nov. 30, 2022	Aug. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	$ 23,301,503	$ 23,943,175
Accumulated amortization	(5,593,193)	(5,102,556)
Total	17,708,310	18,840,619
Land Use Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	11,573,321	11,573,321
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	7,503,709	8,059,386
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	2,292,655	2,320,154
Brand Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	$ 1,931,818	$ 1,990,314

Schedule of Expected Amortizati

Schedule of Expected Amortization Expense of Intangible Assets (Details) - USD ($)	Nov. 30, 2022	Aug. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 2,002,793
2024	2,002,793
2025	1,819,531
2026	1,457,184
2027	1,206,276
Thereafter	9,219,733
Total	$ 17,708,310	$ 18,840,619

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 526,123	$ 619,676

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($)	Nov. 30, 2022	Aug. 31, 2022
Payables and Accruals [Abstract]
Accrued liabilities	$ 972,344	$ 884,024
Accrued payroll	224,394	195,214
Unearned revenue	35,781	36,887
Accrued expenses	$ 1,232,519	$ 1,116,125

Schedule of Governmental Loans

Schedule of Governmental Loans and Note Payable (Details) - USD ($)		Nov. 30, 2022	Aug. 31, 2022
Short-Term Debt [Line Items]
Total government loans and notes payable		$ 157,900	$ 161,460
Less current portion
Long-term portion		157,900	161,460
Notes Payable One [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable	[1]	88,836	91,526
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable		40,320	40,320
Notes Payable Three [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable		$ 28,744	$ 29,614
[1]The Government of Canada launched CEBA loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained CAD$ 80,000 59,224 December 31, 2023 If the loan amount is paid on or before December 31, 2023, 25 75 60,000 20,000 29,612

Schedule of Governmental Loan_2

Schedule of Governmental Loans and Note Payable (Details) (Parenthetical)				3 Months Ended		12 Months Ended
	Jun. 01, 2022	Dec. 14, 2021	Nov. 17, 2021	Nov. 30, 2022 USD ($)	Nov. 30, 2022 CAD ($)	Aug. 31, 2022 USD ($)	Nov. 30, 2022 CAD ($)
Short-Term Debt [Line Items]
Debt instrument, maturity date	Nov. 29, 2022	Jun. 14, 2023	May 17, 2022
Canada Emergency Business Account Loan [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date				Dec. 31, 2023	Dec. 31, 2023
Loans Payable				$ 59,224			$ 80,000
Debt description				If the loan amount is paid on or before December 31, 2023, 25% of the loan will be forgiven (“Early Payment Credit”). In the event that the Company does not repay 75% of such term debt on or before December 31, 2023, the Early Payment Credit will not apply.	If the loan amount is paid on or before December 31, 2023, 25% of the loan will be forgiven (“Early Payment Credit”). In the event that the Company does not repay 75% of such term debt on or before December 31, 2023, the Early Payment Credit will not apply.
Forgiveness percentage				25%	25%
Default in repayment rate				75%	75%
Canada Emergency Business Account Loan [Member] | Terragenx [Member]
Short-Term Debt [Line Items]
Loans Payable				$ 29,612			$ 60,000
Repayment of debt					$ 20,000
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Percentage of interest accrued per annum				3.75%	3.75%	3.75%
Frequency of periodic payment				monthly	monthly	monthly
Debt instrument periodic payment interest				$ 190		$ 190
Debt term				30 years	30 years	30 years
Notes Payable Three [Member]
Short-Term Debt [Line Items]
Percentage of interest accrued per annum				4.53%	4.53%	4.53%
Frequency of periodic payment				annual	annual	annual
Debt instrument periodic payment interest				$ 4,000		$ 4,000
Debt instrument, maturity date				Dec. 31, 2028	Dec. 31, 2028

Schedule of Future Maturities O

Schedule of Future Maturities Outstanding of Governmental Loans and Note Payable (Details)	Nov. 30, 2022 USD ($)
Government Loans And Notes Payable
2023	$ 6,242
2024	95,079
2025	6,242
2026	6,242
2027	6,242
Thereafter	37,853
Total	$ 157,900

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)							3 Months Ended
	Dec. 02, 2022 USD ($)	Nov. 30, 2022 USD ($)	Nov. 14, 2022 USD ($)	Jun. 01, 2022 USD ($)	Dec. 14, 2021 USD ($) $ / shares shares	Nov. 17, 2021 USD ($) $ / shares shares	Nov. 30, 2022 USD ($)	Nov. 30, 2021 USD ($)	Jan. 04, 2023 USD ($)	Aug. 31, 2022 USD ($)
Debt interest amount					$ 16,666,666	$ 1,875,000
Debt face amount						$ 1,875,000				$ 225,924
Interest rate				1%	5%	1%
Maturity date				Nov. 29, 2022	Jun. 14, 2023	May 17, 2022
Share Price | $ / shares					$ 2
Warrants to purchase common stock | shares					5,833,334	223,880
Common stock price per share | $ / shares					$ 2	$ 3.35
Warrants maturity date					Dec. 14, 2025	Nov. 17, 2024
Estimated value of warrants					$ 7,680,156	$ 51,240
Discount on convertable note and additional paid in capital					5,257,466	295,824
Original issue discount					1,666,666	375,000
Loan fees					1,140,000	90,000
Debt discount		$ 2,750,917				$ 760,824	$ 2,750,917
Debt discount		1,490,513					$ 1,490,513	$ 57,840
Incarese in Interest rate							15%
Payment of debt							$ 48,480	$ 3,127
Debt conversion price | $ / shares						$ 3.35
Jefferson Street Letter Agreement [Member]
Debt face amount				$ 946,875
Interest rate				1%
Maturity date				Nov. 29, 2022
Subsequent Event [Member]
Debt face amount									$ 1,000,000
Subsequent Event [Member] | Jefferson Street Letter Agreement [Member]
Debt interest amount	$ 746,875
Partial payment	$ 200,000
Platinum Point Capital LLC [Member]
Payment of debt				$ 948,874
Terragenx Inc [Member]
Debt face amount				$ 946,875
Ownership Percentage						91%
Convertible Debt [Member]
Debt instrument aggregate principal amount
Accrued interest
Warrant [Member]
Debt face amount					$ 5,257,466	$ 295,824
Measurement Input, Expected Term [Member]
Warrants and rights outstanding, term			6 months 29 days		4 years	3 years
Measurement Input, Price Volatility [Member]
Measurement input percentage			148.20		275	300
Measurement Input, Expected Dividend Rate [Member]
Measurement input percentage			0		0	0
Measurement Input, Risk Free Interest Rate [Member]
Measurement input percentage			0.0455		0.0123	0.85
Two Convertible Notes Payable [Member]
Debt face amount					$ 8,333,333	$ 937,500
Convertible Notes Payable [Member]
Debt face amount					11,409,200	$ 1,579,176
Loan fees			$ 1,000,000
Debt discount					$ 8,064,132
Debt instrument description			(i) the conversion price in effect at such time and (ii) 82.0% of the lowest VWAP during the five (5) trading days immediately prior to a conversion date. The Company determined that the conversion features of these notes represented embedded derivatives since the notes are convertible into a variable number of shares upon conversion.
Derivative liabilities			$ 1,390,380
Amortization payment							2,936,019
Debt face amount							2,777,778
Debt interest amount							$ 158,241

Debentures, Related Parties (De

Debentures, Related Parties (Details Narrative)

Jun. 01, 2022

Dec. 14, 2021

Nov. 17, 2021 $ / shares

Nov. 02, 2021

Jul. 21, 2020 USD ($)

Sep. 27, 2019

Jan. 31, 2018 USD ($) $ / shares shares

Dec. 02, 2017

Sep. 30, 2013 USD ($)

Nov. 30, 2022 USD ($)

Aug. 31, 2022 USD ($)

Sep. 30, 2013 CAD ($)

Short-Term Debt [Line Items]

Debentures, outstanding

$ 918,439

$ 946,250

Debt interest rate

1%

5%

1%

Debt due date

Nov. 29, 2022

Jun. 14, 2023

May 17, 2022

Debt conversion price | $ / shares

$ 3.35

Repayment of related party debt

$ 267,768

Five Debentures [Member]

Short-Term Debt [Line Items]

Debentures, outstanding

$ 6,225,163

$ 6,402,512

Debt interest rate

8%

8%

Debt due date

Dec. 01, 2023

Sep. 30, 2021

Sep. 30, 2019

Sep. 30, 2016

Debentures [Member]

Short-Term Debt [Line Items]

Debentures, outstanding

$ 3,894,809

Percentage of debt converted

75%

Accrued interest

$ 414,965

Debt converted, shares issued | shares

1,047,588

Debt conversion, description

The per share price used for the conversion of each debenture was $4.11 which was determined as the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price.

Debt conversion price | $ / shares

$ 4.11

Schedule of Lease Related Asset

Schedule of Lease Related Assets and Liabilities (Details) - USD ($)	Nov. 30, 2022	Aug. 31, 2022
Leases
Operating lease assets	$ 2,423,519	$ 2,673,934
Total lease assets	2,423,519	2,673,934
Current liabilities- Operating lease liability	521,358	582,088
Noncurrent liabilities - Operating lease liability	2,010,041	2,185,329
Total lease liability	$ 2,531,399	$ 2,767,417

Schedule of Lease Obligations (

Schedule of Lease Obligations (Details) - USD ($)	Nov. 30, 2022	Aug. 31, 2022
Leases
2023	$ 715,223
2024	571,627
2025	496,959
2026	512,890
2027	422,053
Thereafter	480,427
Total payments	3,199,179
Amount representing interest	(667,780)
Lease obligation, net	2,531,399	$ 2,767,417
Less lease obligation, current portion	(521,358)	(582,088)
Lease obligation, long-term portion	$ 2,010,041	$ 2,185,329

Schedule of Finance Leases (Det

Schedule of Finance Leases (Details) - USD ($)	Nov. 30, 2022	Aug. 31, 2021
Leases
Cost	$ 209,457	$ 209,457
Accumulated amortization	(206,311)	(192,347)
Net book value	$ 3,146	$ 17,110

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details) - USD ($)	Nov. 30, 2022	Aug. 31, 2022
Leases
2023	$ 16,301
2024	2,272
Total payments	18,573
Amount representing interest	(370)
Lease obligation, net	18,203
Less lease obligation, current portion	(8,737)	$ (8,890)
Lease obligation, long-term portion	$ 9,466	$ 12,076

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	3 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Leases
Lease expense	$ 209,846	$ 216,905
Cash paid under operating leases	$ 202,465	$ 207,683
Weighted average remaning lease term	3 years 11 months 12 days
Weighted average discount rate	8%
Lease payments implicit borrowing rate	5%

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - USD ($)	3 Months Ended	12 Months Ended
	Nov. 30, 2022	Aug. 31, 2022
Equity [Abstract]
Options outstanding, beginning balance	2,164,235
Weighted average exercise price, outstanding, beginning balance	$ 2.15
Weighted average remaining contractual life, outstanding, ending balance	2 years 2 months 23 days	2 years 6 months 10 days
Aggregate intrinsic value, beginning balance	$ 140,577
Options, granted
Options, forfeited
Options, exercised
Options outstanding, ending balance	2,164,235	2,164,235
Weighted average exercise price, outstanding, ending balance	$ 2.17	$ 2.15
Aggregate intrinsic value, ending balance		$ 140,577
Options outstanding, exercisable	2,070,240
Weighted average exercise price, exercisable	$ 2.21
Weighted average remaining contractual life, exercisable	2 years 1 month 20 days
Aggregate intrinsic value, exercisable

Schedule of Options Outstanding

Schedule of Options Outstanding (Details) - $ / shares	Nov. 30, 2022	Aug. 31, 2022
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	2,164,235	2,164,235
Number of options, exercisable	2,070,240
Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	227,155
Number of options, outstanding, exercise price	$ 1.33
Number of options, exercisable	133,160
Number of options, exercisable, exercise price	$ 1.33
Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	992,000
Number of options, outstanding, exercise price	$ 1.60
Number of options, exercisable	992,000
Number of options, exercisable, exercise price	$ 1.60
Exercise Price Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	48,000
Number of options, outstanding, exercise price	$ 1.87
Number of options, exercisable	48,000
Number of options, exercisable, exercise price	$ 1.87
Exercise Price Range Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	775,000
Number of options, outstanding, exercise price	$ 3
Number of options, exercisable	775,000
Number of options, exercisable, exercise price	$ 3
Exercise Price Range Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	72,600
Number of options, outstanding, exercise price	$ 3.80
Number of options, exercisable	72,600
Number of options, exercisable, exercise price	$ 3.80
Exercise Price Range Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	10,000
Number of options, outstanding, exercise price	$ 5
Number of options, exercisable	10,000
Number of options, exercisable, exercise price	$ 5
Exercise Price Range Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options, outstanding	39,480
Number of options, outstanding, exercise price	$ 1.90
Number of options, exercisable	39,480
Number of options, exercisable, exercise price	$ 1.90

Schedule of Fair Value of Optio

Schedule of Fair Value of Options Granted by Using Valuation Assumptions (Details)	3 Months Ended
	Nov. 30, 2022	Nov. 30, 2021
Risk-free interest rate		0.93%
Expected life of the options	2 years 6 months	2 years 6 months
Expected volatility	281%	282%
Expected dividend yield	0%	0%
Minimum [Member]
Risk-free interest rate	0.93%
Maximum [Member]
Risk-free interest rate	1.89%

Schedule of Warrant Activity (D

Schedule of Warrant Activity (Details)	3 Months Ended
	Nov. 30, 2022 USD ($) $ / shares shares
Equity [Abstract]
Warrants outstanding, beginning balance	8,445,264
Weighted average exercise price, outstanding, beginning balance | $ / shares	$ 2.42
Weighted average remaining contractual life, outstanding, beginning balance	3 years 9 months
Aggregate intrinsic value, outstanding, beginning balance | $
Warrants outstanding, granted	8,000,000
Weighted average exercise price, granted | $ / shares	$ 0.10
Warrants outstanding, forfeited
Warrants outstanding, exercised	(4,673,986)
Warrants outstanding, ending balance	11,771,278
Weighted average exercise price, outstanding, ending balance | $ / shares	$ 0.81
Weighted average remaining contractual life, outstanding, ending balance	3 years 9 months 3 days
Aggregate intrinsic value, outstanding, ending balance | $	$ 1,483,425
Warrants outstanding, exercisable	11,771,278
Weighted average remaining contractual life, exercisable	3 years 9 months 3 days
Aggregate intrinsic value, exercisable | $	$ 1,483,425

Schedule of Exercise Price of W

Schedule of Exercise Price of Warrants Outstanding (Details)	Nov. 30, 2022 $ / shares shares
Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants, Outstanding and Exercisable	1,159,348
Number of Options, Outstanding and Exercisable, Exercise Price | $ / shares	$ 0
Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants, Outstanding and Exercisable	2,611,930
Number of Options, Outstanding and Exercisable, Exercise Price | $ / shares	$ 3.35
Exercise Price Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants, Outstanding and Exercisable	8,000,000
Number of Options, Outstanding and Exercisable, Exercise Price | $ / shares	$ 0.10
Exercise Price Range [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants, Outstanding and Exercisable	11,771,278

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)			3 Months Ended
	Oct. 13, 2022	Feb. 09, 2021	Nov. 30, 2022	Nov. 30, 2021	Nov. 21, 2022	Oct. 31, 2022	Aug. 31, 2022	Dec. 14, 2021	Jan. 16, 2018	Sep. 08, 2015
Accumulated Other Comprehensive Income (Loss) [Line Items]
Convertible preferred stock, shares authorized			1,000,000				1,000,000
Convertible preferred stock, par value			$ 0.001				$ 0.001
Convertible preferred stock, shares issued			0				0
Convertible preferred stock, shares outstanding			0				0
Common stock, shares authorized			499,000,000				499,000,000
Common stock, par value			$ 0.001				$ 0.001
Number of restricted shares			39,890,811				31,180,603
Common stock, shares outstanding			39,890,811				31,180,603
Share price								$ 2
Stock issued during period shares other			4,000,000
Proceeds from issuance of common stock			$ 2,000,000
Purchase share			4,000,000
Exercise price share			$ 0.50
Exercise price share			$ 0.50
Issuance of private placement			$ 140,000
Percentage of issuance of private placement			7%
Repayments of debt			$ 1,795,000
Shares granted			8,000,000
Shares granted			1,137,959
Expected Voltality			281%	282%
Dividend yield			0%	0%
Risk free interet rate				0.93%
Expected life			2 years 6 months	2 years 6 months
Options granted			0
Weighted average fair value				$ 3.76
Weighted-average exercise price				$ 3.80
Stock option expense			$ 60,887	$ 154,135
Unamortized stock option expense			$ 60,887
2015 Incentive Compensation Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares available for future grant			498,750
2018 Incentive Compensation Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of common stock shares authorized									1,000,000
Number of shares available for future grant			864,900
2021 Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of common stock shares authorized		4,500,000
Number of shares available for future grant			3,754,665
Term of award description		the maximum aggregate number of shares that may be issued under the 2021 Plan is eligible to be cumulatively increased on January 1, 2022 and on each subsequent January 1 through and including January 1, 2023, by a number of shares equal to the smaller of (i) 3% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (ii) an amount determined by our Board of Directors. The Company chose not to cumulatively increase the shares authorized for issuance under the 2021 Plan effective January 1, 2023. As of November 30, 2022, the 2021 Plan had 3,754,665 shares available for award
Acenzia Terragenx [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares issued for acquisition, shares			4,113,411
Share Exchange Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of restricted shares			36,222
Shares issuance date			Oct. 26, 2022
Hudson Bay [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of restricted shares			2,916,667
Shares issuance date			Nov. 15, 2022
CVI [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of restricted shares			1,757,319
Shares issuance date			Nov. 15, 2022
Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Risk free interet rate			0.93%
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Risk free interet rate			1.89%
Maximum [Member] | 2015 Incentive Compensation Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of common stock shares authorized										500,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Unit offering, shares	4,000,000
Share price					$ 1	$ 0.50
Unit offering description			The Company sold an aggregate of 4,000,000 units for aggregate gross proceeds of $2,000,000, consisting of 4,000,000 common stock, 4,000,000 warrants with a three-year term to purchase 4,000,000 shares of common stock at an exercise price of $0.50 per share, and 4,000,000 warrants with a five-year term to purchase 4,000,000 shares of common stock at an exercise price of $0.50 per share
Stock issued during period shares other			4,000,000	2,000,000
Purchase share			4,000,000
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued during period shares other			4,000,000
Dividend yield			0%
Share issued price per share			$ 0.2956
Warrant [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected Voltality			149.06%
Expected life			3 years
Warrant [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Risk free interet rate			2.55%
Warrant [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expected Voltality			206.90%
Expected life			5 years
Warrant [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Risk free interet rate			2.89%

Schedule of Segment Reporting I

Schedule of Segment Reporting Information (Details) - USD ($)	3 Months Ended
	Nov. 30, 2022	Nov. 30, 2021	Aug. 31, 2022	Aug. 31, 2021
Segment Reporting Information [Line Items]
Sales	$ 3,419,280	$ 3,161,927
Gross profit	1,739,533	1,266,466
Loss from operations	(2,241,960)	(1,363,659)
Depreciation and amortization	586,166	694,282
Capital expenditures		120,397
Interest expenses	167,243	68,730
Net loss	(3,936,736)	(1,816,395)
Total assets	37,748,823		$ 40,872,840
Accounts receivable	960,091		1,017,405
Intangible assets	17,708,310		18,840,619
Goodwill	7,595,844		7,825,844	$ 9,488,848
Healthcare Services [Member]
Segment Reporting Information [Line Items]
Sales	2,021,213	2,179,623
Gross profit	784,031	799,642
Loss from operations	(151,691)	(111,105)
Depreciation and amortization	28,968	74,606
Capital expenditures		104,842
Interest expenses	36,303	20,127
Net loss	(185,713)	(128,807)
Total assets	5,662,841		5,917,403
Accounts receivable	637,434		585,492
Intangible assets	146,169		159,453
Goodwill	521,740		537,537
Product Manufacturing And Development [Member]
Segment Reporting Information [Line Items]
Sales	790,478	982,304
Gross profit	347,914	466,824
Loss from operations	(554,842)	(341,545)
Depreciation and amortization	309,042	252,076
Capital expenditures		15,555
Interest expenses	2,464	48,603
Net loss	(578,576)	(782,542)
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Sales	607,589
Gross profit	607,588
Loss from operations	(1,535,427)	(911,009)
Depreciation and amortization	248,156	367,600
Capital expenditures
Interest expenses	128,476
Net loss	(3,172,447)	$ (905,046)
Total assets	13,602,753		15,360,168
Accounts receivable			12,496
Intangible assets	13,118,390		13,397,832
Goodwill
Product Sales [Member]
Segment Reporting Information [Line Items]
Total assets	18,483,229		19,595,269
Accounts receivable	322,657		419,417
Intangible assets	4,443,751		5,283,333
Goodwill	$ 7,074,104		$ 7,288,307

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)

3 Months Ended

6 Months Ended

Feb. 24, 2024

Jan. 24, 2024

Dec. 23, 2023

Dec. 21, 2023

Nov. 23, 2023

Nov. 21, 2023

Oct. 23, 2023

Oct. 21, 2023

Sep. 23, 2023

Sep. 21, 2023

Aug. 23, 2023

Apr. 26, 2023

Apr. 24, 2023

Apr. 21, 2023

Mar. 21, 2023

Feb. 23, 2023

Jan. 23, 2023

Jan. 04, 2023

Dec. 23, 2022

Dec. 02, 2022

Jun. 01, 2022

Dec. 14, 2021

Nov. 17, 2021

Nov. 30, 2022

May 19, 2023

May 17, 2023

May 24, 2023

Dec. 30, 2022

Dec. 27, 2022

Nov. 21, 2022

Oct. 31, 2022

Aug. 31, 2022

Subsequent Event [Line Items]

Debt instrument, face amount

$ 1,875,000

$ 225,924

Share price

$ 2

Debt instrument, maturity date

Nov. 29, 2022

Jun. 14, 2023

May 17, 2022

Debt interest rate

1%

5%

1%

Notes payable

$ 16,666,666

$ 1,875,000

Original issue discount

1,666,666

$ 375,000

Debt instrument, conversion price

$ 3.35

Exercise price of warrants or rights

$ 0.50

Jefferson Street Letter Agreement [Member]

Subsequent Event [Line Items]

Debt instrument, face amount

$ 946,875

Debt instrument, maturity date

Nov. 29, 2022

Debt interest rate

1%

Mast Hill Securities Purchase Agreement [Member] | Forecast [Member]

Subsequent Event [Line Items]

Debt periodic payment

$ 100,000

$ 100,000

$ 57,300

$ 57,300

$ 57,300

$ 100,000

First Fire Securities Purchase Agreement [Member] | Forecast [Member]

Subsequent Event [Line Items]

Debt periodic payment

$ 100,000

$ 100,000

$ 100,000

$ 57,300

$ 57,300

$ 57,300

Warrant [Member]

Subsequent Event [Line Items]

Debt instrument, face amount

$ 5,257,466

$ 295,824

Common Stock [Member]

Subsequent Event [Line Items]

Number of shares issued upon note conversions

4,441,359

Stock issued during period, shares, new issues

4,000,000

Share price

$ 1

$ 0.50

Subsequent Event [Member]

Subsequent Event [Line Items]

Number of shares issued upon note conversions

94,185,340

Debt instrument, face amount

$ 1,000,000

Conversion rate

82%

Subsequent Event [Member] | Jefferson Street Letter Agreement [Member]

Subsequent Event [Line Items]

Partial payment

$ 200,000

Notes payable

$ 746,875

Subsequent Event [Member] | Swag Check Agreement [Member]

Subsequent Event [Line Items]

Proceeds from financing commitment

$ 90,000,000

$ 92,000,000

Proceeds from distributed directly to Receiver

60,000,000

60,000,000

$ 60,000,000

Proceeds from distributed for benefit of outgoing shareholders

$ 30,000,000

$ 32,000,000

Subsequent Event [Member] | Mast Hill Securities Purchase Agreement [Member]

Subsequent Event [Line Items]

Debt instrument, face amount

$ 573,000

Stock issued during period, shares, new issues

955,000

Debt instrument, maturity date

Feb. 23, 2024

Debt instrument, interest rate, effective percentage

12%

Class of warrant or right, number of shares

27,720,448

Original issue discount

$ 57,300

Payments for repurchase of warrants

$ 515,700

Debt instrument, conversion price

$ 0.175

Percentage of stock price trigger

85%

Administrative fees expense

$ 750

Variable interest, percentage rate

125%

Exercise price of warrants or rights

$ 0.25

Percentage of issued and outstanding common stock

19.99%

Interest paid

$ 5,840

$ 5,086

Subsequent Event [Member] | Mast Hill Securities Purchase Agreement [Member] | Maximum [Member]

Subsequent Event [Line Items]

Class of warrant or right, number of shares

1,000,000

Variable interest, percentage rate

16%

Subsequent Event [Member] | First Fire Securities Purchase Agreement [Member]

Subsequent Event [Line Items]

Debt instrument, face amount

$ 573,000

Stock issued during period, shares, new issues

955,000

Debt instrument, maturity date

Mar. 21, 2024

Debt instrument, interest rate, effective percentage

12%

Class of warrant or right, number of shares

10,000,000

Original issue discount

$ 57,300

Payments for repurchase of warrants

$ 515,700

Debt instrument, conversion price

$ 0.175

Percentage of stock price trigger

85%

Administrative fees expense

$ 750

Variable interest, percentage rate

125%

Exercise price of warrants or rights

$ 0.25

Interest paid

$ 5,730

Subsequent Event [Member] | First Fire Securities Purchase Agreement [Member] | Maximum [Member]

Subsequent Event [Line Items]

Class of warrant or right, number of shares

1,000,000

Variable interest, percentage rate

16%

Subsequent Event [Member] | RC Consulting Group SPA [Member]

Subsequent Event [Line Items]

Debt instrument, maturity date

Apr. 26, 2038

Debt interest rate

1.52%

Unsecured debt principal amount

$ 70,000,000

Purchase price

$ 57,000,000

Debt instrument description

a liquidated damages charge of 25% of the outstanding principal balance of the RC Note, but not less than $1,000,000, will be assessed and will become immediately due and payable to the RC Noteholder at its election in the form of a cash payment or added to the balance of the RC Note (under the RC Noteholder’s and the Company’s expectation that this amount will tack back to the date of issuance of the RC Note).

Debt interest rate

125%

Subsequent Event [Member] | CVI Investments Inc [Member]

Subsequent Event [Line Items]

Debt instrument, face amount

$ 0

Convertible debt

$ 0

Subsequent Event [Member] | Jefferson [Member]

Subsequent Event [Line Items]

Convertible debt

0

Subsequent Event [Member] | Hudson Bay Master Fund Ltd [Member]

Subsequent Event [Line Items]

Debt instrument, face amount

$ 0

$ 0

Subsequent Event [Member] | Warrant [Member]

Subsequent Event [Line Items]

Number of shares issued

3,910,000

Subsequent Event [Member] | NHL Non-Voting Special Shares [Member]

Subsequent Event [Line Items]

Stock issued during period, shares, new issues

3,202,019

Subsequent Event [Member] | Common Stock [Member] | Swag Check Agreement [Member]

Subsequent Event [Line Items]

Share price

$ 1

Percentage of stock issued and outstanding

100%